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Abstract 
 
A series of monothiosemicarbazone (and dithiosemicarbazone) ligands have been 
synthesized via a Schiff base condensation reaction. These ligands contain various 
aromatic groups and were isolated as solids in moderate to good yields. The ligands 
were characterized using various spectroscopic and analytical techniques. 
 
Selected ligands were subsequently reacted with the highly air- and moisture-
sensitive GaCl3 generating gallium(III) thiosemicarbazone complexes. These 
complexes were fully characterized using spectroscopic and analytical techniques. 
The series of ligands were tested for their radiolabelling ability with 67Ga (in the form 
of 67GaCl3). The successfully radiolabelled complexes (with labelling efficiencies 
ranging from 87 % to more than 99 %) were tested for their chemical stability in 
saline and bovine serum. The effect of water on the radiolabelling efficiency of these 
ligands was also tested. 
 
The biological cellular uptake of the chemically stable radiolabelled complexes were 
evaluated against the rat ovarian cancer (DMBA OC1R) cells, the human breast 
cancer (MCF 7) cells and the non-cancerous brain endothelial (bEND5) cells. The 
radiolabelled complexes show better uptake into the non-cancerous brain endothelial 
cells compared to the cancer cells. However, this could possibly be due to the faster 
cell kinetics of the brain endothelial cells compared to the cancer cells, which is 
contrary to what happens in vivo. The mononuclear complex shows better uptake into 
the cells compared to the binuclear complex. 
 
A preliminary investigation into the synthesis of radiolabelled palladium 
poly(aryl)ether dendrimers was also undertaken. Two new dendritic poly(aryl)ether 
ligands were synthesized in moderate yields. These ligands were characterized using 
various spectroscopic and analytical techniques. These ligands were subsequently 
reacted with previously synthesized PdCl2(cyclooctadiene) to afford dendritic 
(generation 0 and generation 1) poly(aryl)ether complexes, which were also 
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viii 
characterized. The ligands were tested for their radiolabelling ability with 109Pd (in the 
form of 109PdCl2) in different organic solvents (ethanol, acetonitrile and 
dichloromethane).  The reaction mixtures were analyzed using a HPLC coupled to a 
radiodetector. There are no signs of formation of a radiolabelled complex using 
ethanol or acetonitrile as reaction solvents. There is, however, a currently unidentified 
peak in the HPLC chromatogram, found when analyzing the reaction mixture in 
dichloromethane as reaction solvent. This peak could not be further analyzed due to 
the rate of decay of 109Pd. Thus, further investigations will have to be performed. 
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Abbreviations 
 
°C    degrees Celsius 
%    percentage 
 
Br    broad 
 
13C{1H}-NMR   carbon-13 proton-decoupled nuclear magnetic resonance 
COD    cyclooctadiene 
 
d    doublet 
DCM    dichloromethane 
DMSO   dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
dNDP    deoxynucleoside diphosphate 
 
E.A.    elemental analysis 
en    ethylenediamine 
EPR    enhanced permeability and retention 
EI    electron impact (mass spectrometry) 
ESI    electronspray ionization (mass spectrometry) 
Et    ethyl 
 
FT-IR    Fourier-transform infrared spectroscopy 
 
g    gram(s) 
 
hrs    hours 
1H-NMR   proton nuclear magnetic resonance 
HPLC    High-performance Liquid Chromatography 
HSQC    heteronuclear single quantum correlation 
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x 
Hz    hertz 
IR    infrared 
 
J    coupling constant 
 
keV    kilo (1000) electron volts 
 
µCi    microcurie 
µL    microlitre(s) 
m    multiplet (NMR) 
m    meta- (NMR);medium intensity (IR) 
Me    methyl 
MHz    megahertz 
min.    minute(s) 
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mL    millilitre(s) 
mol.    mole(s) 
mmol.    millimole(s) 
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MS    mass spectrometry 
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NMR    nuclear magnetic resonance 
NECSA   South African Nuclear Energy Corporation 
 
o    ortho- 
p    para- 
PAMAM   poly(amidoamine) 
PET    Positron Emission Tomography  
PPh3    triphenylphosphine 
ppm    parts per million 
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xi 
rt.    room temperature 
 
s    singlet (NMR) 
SPECT   Single photon emission computed tomography 
s    strong intensity (IR) 
 
t    triplet (NMR) 
THF    tetrahydrofuran 
 
w    weak intensity (IR) 
WHO    World Health Organization 
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Chapter 1 
 
Literature Review 
 
1.1. General Introduction 
 
Cancer is one of the leading causes of death worldwide.1  It has been reported to 
account for 7.4 million deaths (around 13% of all deaths) in 2004.2  According to later 
World Health Organisation (WHO) statistics, cancer causes an estimated 7.9 million 
deaths worldwide each year, with more than 30% of cancer deaths being 
preventable.1,2  Of the 7.9 million deaths each year, it is estimated that more than 
72% are now occurring in low- and middle-income countries.1  Lung, stomach, liver, 
colon and breast cancer has been reported to cause the most cancer deaths each 
year.2  Deaths from cancer worldwide are projected to continue rising, with an 
estimated 12 million deaths in 2030.2 
Cancer is the uncontrolled growth and spread of tumour cells that can affect almost 
any part of the body.3 The growths often invade surrounding tissue and can 
metastasize to different and distant sites in the body.3 Metastasis is defined as a 
secondary cancerous growth formed by transmission of cancerous cells from a 
primary growth located elsewhere in the body.4 Cancer arises from a change in one 
single cell, which could be started by external agents and inherited genetic factors.  
The transformation of a normal cell into a tumour cell is a multistage process, usually 
a progression from a pre-cancerous lesion to a malignant tumour.  This progression 
is a result of the interaction between someone’s genetic factors and three categories 
of external agents: 
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 Chemical carcinogens → such as asbestos, components of tobacco 
smoke, aflatoxin (a food contaminant) and arsenic (a drinking water 
contaminant). 
 Biological carcinogens → such as infections from certain viruses, bacteria 
or parasites. 
 Physical carcinogens → such as ultraviolet and ionizing radiation.2 
Ageing is another fundamental factor with the incidence of cancer rising with age.  
This is most likely due to the build-up of risks for specific cancers that increase with 
age.  The overall risk accumulation is combined with the tendancy for cellular repair 
mechanisms to be less effective as the person grows older.2 
Early detection of cancer is a vital preventative measure purely based on the 
observation that treatment is more effective when the cancer is detected early.  The 
aim is to detect the cancer when it is localized (i.e. before metastasis).  The efforts 
into early detection consist of two components: 
 Education → to help people recognize the early signs of cancer. 
 Screening programmes → to identify early cancer or pre-cancer before 
signs are recognizable. 
In addition, a significant proportion of cancers can be cured by surgery, 
chemotherapy or radiotherapy, especially if they are detected early.3 In recent years 
metal complexes have gained increased attention as chemotherapeutic drugs and 
diagnostic tools (i.e. radiopharmaceuticals).5  
1.2. Radiopharmaceuticals 
A radiopharmaceutical (nuclear medicine) is a radioactive compound that is nothing 
else but the combination of a radioisotope of an element with a new molecule 
(complexes, perfusion agent) or with a molecule of well known biological behaviour 
(targeting).6  It has also been described as the in vivo use of drugs labelled with 
radioactive atoms (radioisotopes) for the detection and therapy of diseases such as 
cancer.7 Radioisotopes have primarily been associated with cancer as causal 
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agents, however, more recently the beneficial side has emerged as radioisotopes 
are now employed for tumour imaging and therapy.7  
Radioisotopes are known to decay by emitting gamma-rays (high energy 
electromagnetic radiation) or particles, such as betas (electrons). These are the 
metal characteristics needed for use in radiopharmaceutical development. Gamma 
rays (especially with energies between 100-200 KeV) are usually highly penetrating 
in tissue and are thus useful for external imaging. Beta-particles have a much shorter 
penetration range in tissue and can therefore provide a localized therapeutic 
radiation dose.6 
A number of radioisotopes in diverse chemical forms have been shown to 
accumulate in tumours relative to surrounding normal tissue such that these tumours 
may be detected by external imaging devices.7 In certain cases the tumours are 
treated by the radiation they emit.7 For example, radioisotopes of iodine (131I, 123I) as 
iodides are useful for the detection and, in the case of 131I, the treatment of thyroid 
carcinomas.7 Gallium-67 (67Ga) citrate is a preferred imaging agent for soft-tissue 
tumours, technetium-99m (99mTc) phosphates and phosphonates have proven to be 
useful in the detection of bone metastasis, and radioisotopes of rhenium (188Re, 
186Re) as the dimercaptosuccinic acid chelates are under investigation for the 
therapy of certain tumours.7  
In the early 1990’s, methods for the attachment of 99mTc, the radioiodines, 111In and 
other radioisotopes to monoclonal antibodies specific for tumour-associated antigens 
were developed and, in this form, they were found to be useful for the detection and 
therapy of diverse tumour types.7 It was also found that the radioactive isotopes 67Ga 
and 68Ga show some promise in the study of bone cancer as compounds of these 
isotopes are absorbed by the cancer deposits in the bone.8  The accumulation of 
67Ga was first demonstrated in lymph nodes of patients with Hodgkin’s disease and 
was subsequently found to accumulate in tumours, tissues of inflammation and 
bone.8 The utility of 67Ga in nuclear medicine is variable. Many types of tumours 
have been shown to accumulate 67Ga poorly but others, such as hepatomas and 
lymphomas, tend to be gallium avid. However, the tumours can be inconsistent in 
magnitude and uniformity of uptake. Nonetheless, no other gamma-emitting 
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4 
radiopharmaceutical has surpassed 67Ga in cost-effectiveness, availability and use 
for general tumour imaging.9 
In modern medicine, early diagnosis of diseases plays an important part in improving 
quality of life and reducing health care costs to society. Just as important, however, 
is the detection of curative progress, i.e. the progress made after therapeutic 
treatment of a patient’s disease (eg. the regression of cancer after 
chemotherapy).10,11  On the molecular level, biochemical analytical methods are well 
established. Since the discovery of X-rays, visualizing methods have become more 
important and routine X-rays are nowadays complemented with the use of magnetic 
resonance imaging (MRI), ultrasound and radioisotope-based scintigraphy.6 While X-
ray and MRI are structural methods, positron emission tomography (PET) or single 
photon emission computed tomography (SPECT) permit the visualization of organ 
functions and are hence functional diagnostic methods.6 Both methods, PET and 
SPECT, are based on radionuclides and are included in nuclear medicine and/or 
radiopharmacy.6 
PET and SPECT are nuclear medicine imaging techniques which produce three-
dimensional images or pictures of functional processes in the body. These imaging 
techniques could allow for early detection of cancers. Both are non-invasive 
techniques which merely require an injection of the radionuclidic compound, which is 
normally attached to a biologically active molecule, into the bloodstream of the 
patient, followed by detection of the emitted radiation by means of a PET or SPECT 
camera. PET imaging makes use of radioisotopes with short half-lives (i.e. usually up 
to 2 hours). The system detects pairs of gamma rays, formed inside the body during 
the collision of a positron, generated by a positron-emitting radionuclide, with an 
electron (electron-positron annihilation). SPECT imaging, however, makes use of 
radioisotopes with longer half-lives (e.g. 67Ga-citrate is used as a SPECT tracer with 
a half life of 78 hours). The system detects gamma rays emitted directly by a 
gamma-emitting isotope. 
In addition, there are factors that influence the stability of the radiolabel in vivo, and 
obviously the instability, which results in the loss of the radiolabel in circulation, will 
contribute to low tumour accumulations.7 Losses occurring in the tumour tissue will 
also result in low tumour accumulation if the free radiolabel is capable of diffusing 
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therefrom.7 Most cancer therapeutics (chemo, antibody-based, radiation) are at best 
only partially and/or temporarily effective.  In general, the causes for failure can be 
summarized as: (i) poor diffusion and/or nonuniform distribution of drug molecules in 
solid tumours; (ii) high drug concentration and retention in normal tissues (leading to 
side effects); (iii) requirement for plasma-membrane permeability; (iv) low uptake of 
drug by tumour; and (v) lack of retention of the drug within the tumour.12 Thus, there 
is an increase in research into developing new metal-containing anti-cancer and 
imaging drugs. 
1.3. Metal-containing anti-cancer/imaging compounds 
Novel antitumour drugs possessing a strong inhibitory effect on ribonucleotide 
reductase would prove to be a useful addition to existing therapeutic regimens for 
the treatment of cancer.13 Ribonucleotide reductase is known to be an essential 
enzyme for cellular respiration.13 The reductive conversion of ribonucleotides to 
deoxyribonucleotides by the iron-dependent enzyme ribonucleotide reductase has 
been reported to be a crucial rate-controlling step in the pathway leading to the 
biosynthesis of deoxyribonucleic acids (DNA).13-18 Thus inhibition of the iron binding 
site in ribonucleotide reductase could prove to be key in proliferating tumour cells. 
Ribonucleotide reductase is thus considered to be an excellent target for cancer 
chemotherapy.16 
 
 
 
Pt
ClCl
H3N NH3 
 
Fig. 1.1: The structure of cisplatin, one of the best selling anticancer drugs 
 
The field of medicinal chemistry has been dominated by the synthesis of organic 
compounds as medicinal drugs but metal complexes have gained considerable 
attention in the field as pharmaceuticals17 for use as diagnostic tools or as 
chemotherapeutic drugs against cancer.5  Research in medicinal chemistry has been 
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stimulated by the worldwide success of cisplatin (Fig. 1.1), cis-
diamminedichloroplatinum(II), which is one of the best selling anticancer drugs.5  
Cisplatin was first synthesized in 1844 by Michel Peyrone5, but its anti-cancer 
properties were only discovered by chance more than a century later, in the 1960’s, 
by Barnett Rosenberg as a result of an investigation looking at the effect of electric 
fields on the growth of bacteria using platinum electrodes.5,18  The mode of action of 
cisplatin is now widely accepted to be through the interaction of the drug with DNA.5  
Since the discovery of the anticancer properties of cisplatin, there has been 
considerable effort made in the design of drugs based on platinum and other metals.  
Some of the most promising recent developments are in the fields of ruthenium and 
gallium complexes, where some of these complexes have successfully undergone 
Phase I and II human clinical trials.5 An important issue is the development of drugs 
that could be taken orally, rather than by intravenous injection. To achieve this, the 
active metal would have to be bound to the right type of organic ligand in order for 
the resultant complex to survive the harsh stomach environment, be absorbed in the 
intestine and then slowly release the active component in the blood plasma or 
tumour. 
The essential role of metal ions, especially transition metal ions, in biological 
systems is well known.5  The wide range of coordination numbers and geometries, 
accessible redox states, thermodynamic and kinetic characteristics, and the intrinsic 
properties of the cationic metal ion and ligand itself offer the medicinal chemist a 
wide spectrum of reactivities that can be exploited.19  Studies of metal complexes 
have thus drawn considerable attention, and are growing increasingly more 
important, as chemotherapeutic drugs in the treatment of cancer.5,20  Metal-
complexed anticancer prodrugs may be activated selectively in the hypoxic tumour 
tissue upon reduction by biological reducing agents.21-23  Electron transfer can occur 
either to the metal center or to the binding ligand resulting in reactive species 
capable of attacking biologically relevant target molecules either by ligand 
displacement at the low valent metal center or by radicals formed at the ligand entity, 
respectively.21   
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1.3.1. Platinum-based complexes 
 
Although metals have long been used in medicinal chemistry, the potential of metal-
based agents has only fully been realized since the discovery of the biological 
properties of cisplatin, a platinum-based anticancer drug.19,24-26 It has been reported 
that, in addition to its intrinsic tumour-killing ability, cisplatin has been shown to work 
in synergy with external radiation. Thus, the use of cisplatin in combination with 
external radiation provides greater levels of tumour killing than either modality 
alone.27 So, in order to take advantage of the radiation-enhancing effects of cisplatin, 
a radioactive form of cisplatin as a cancer therapy agent was proposed in a patent by 
Wayne Court and Isotope Solutions, Inc. (patent number WO/2003/000298).28  
 
M
H3N NH3
O O
O O
M = Pt-191, Pt-193m
 
Fig. 1.2: Structural representation of 191Pt-labelled and 193mPt-labelled 1,1-cyclobutanedicarboxylate 
diammine platinum(II). 
 
It has also been reported that other radiolabelled platinum drugs, such as 191Pt-
labelled 1,1-cyclobutanedicarboxylate diammine platinum(II) (Fig. 1.2), 193mPt-
labelled 1,1-cyclobutanedicarboxylate diammine platinum(II) (Fig. 1.2) and 191Pt-
labelled cis-dichloro-trans-dihydroxybis-isopropylamine platinum(IV), could have 
therapeutic uses.28  
 
However, it should be noted that platinum-based drugs show activity against a 
limited number of tumours.5 In addition, there are often significant side effects, such 
as neurotoxicity, nephrotoxicity, myelosuppression and the problem of developing 
drug resistance during treatment.5,29 
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1.3.2. Ruthenium-based complexes 
 
Various aspects of the advances in the development of tumour-inhibiting ruthenium-
complexed drugs have been reviewed since the late 1990’s.5,30,31  Among the most 
remarkable achievements in ruthenium-based anticancer research is the entering 
into phase I clinical trials of the ruthenium-based complex, NAMI-A (Fig. 1.3) in 1999 
by Allessio et al.32 Another ruthenium(II) complex, Hind[trans-RuCl4(ind)2] (i.e. 
KP1019 – Fig. 1.3), developed by Keppler and co-workers33 has attracted attention 
as a potential anticancer agent and has since entered clinical trials. 
 
H
N
HN
HN
N
Ru
Cl
Cl
Cl
Cl
NH
N
Ru
Cl
Cl
Cl
Cl
S
N
O
NH
N
H
H
N
NAMI-A
KP1019  
Fig. 1.3: The structural representation of NAMI-A (left) and KP1019 (right). 
 
Research into other ruthenium complexes such as [(η6-p-cymene)Ru(II)Cl(en)]PF6 
has made a serious contribution to getting an insight into the mode of action of this 
class of organometallic antitumour compounds.5  The compound [(η6-p-
cymene)Ru(II)Cl(en)]PF6 has been shown to undergo rapid hydrolysis in aqueous 
solution resulting in the substitution of the chloride ligand by a water molecule.34  The 
presence of hydrophobic planar ligands in these types of ruthenium-complexes may 
facilitate recognition and transport of these species through cell membranes.34  It 
should also be noted that hydrophobic derivatives showed higher tumour-inhibiting 
activity.34  The relative conformational flexibility of the ligands makes the intercalation 
into DNA with simultaneous binding of ruthenium(II) to DNA compatible.34 DNA was 
supposed to be the main target for these complexes. The complex [(η6-p-
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cymene)Ru(II)Cl(en)]PF6 has been found to distort duplex DNA structure by forming 
monofunctional adducts with the guanine base.34 These results have provided 
conditions for optimisation of ruthenium-arene DNA interactions to achieve higher 
anticancer activity.34 
 
Research into ruthenium complexes as anti-cancer compounds has also led to the 
design of possible ruthenium imaging agents. In 2007, Sadler and co-workers35 
synthesized a ruthenium radiolabelled complex, [(6-fluorene)106Ru(en)Cl]PF6 (Fig. 
1.4). This was the first reported example of a prospective ruthenium anti-tumour 
agent which has been radiolabelled and used in biodistribution studies. The 
distribution studies in the tissues of a rat 15 minutes post-injection showed that 106Ru 
was well distributed throughout the body tissues. The highest levels were associated 
with the liver and kidney, with the lower levels being present in the blood, bone 
marrow, brown fat, cartilage, lung, preputial gland, skin/fur, submaxilliary salivary 
glands and testes. This report shows the potential of developing new ruthenium 
complexes as imaging agents.35 
 
Ru
Cl
NH2H2N
106
PF6
 
 
Fig.1.4: Structure of the ruthenium radiolabelled complex, [(6-fluorene)106Ru(en)Cl]PF6. 
 
1.3.3. Palladium-based complexes 
 
Until developments made by Khan and co-workers36, there had been little or no 
application of palladium complexes as antitumour drugs.29 This is due to the high 
lability and fast hydrolysis reactions presented by palladium complexes in biological 
environments when compared to platinum complexes.29,36 To circumvent this 
problem, Khan and co-workers used chelating ligands in the synthesis of palladium 
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complexes. The results demonstrate that the palladium complex [Pd(meth)(2-
merpy)Cl]Cl (where meth = methionine and merpy = mercaptopyrimidine) has a 
significant cytotoxicity and could act as a powerful antitumour agent.36  Hence, other 
works involving palladium complexes started to have other perspectives of use, 
especially the class of cyclopalladated complexes.29  
 
HN N
H3C
Pd
Cl
Cl
NHN
CH3H3C
CH3
(C)
Pd
Ph
Ph Ph
Ph
Pd
N N
Cl Cl
CH3
H3C
H3C
CH3
H3C
H
CH3
H
(D)  
 
Fig. 1.5: Structures of the trans-palladium complex with pyrazol (C) and the cyclopalladated complex 
[Pd2(C2,N-S(-)dmpa)2(µ-dppe)Cl2] (D). 
 
Many palladium compounds show high activity in cisplatin-resistant cells, which 
might suggest that the biochemical mechanism of action differs to that of cisplatin.  It 
has been suggested that non-covalent interactions (such as major/minor groove 
binding, electrostatic interaction, intercalation and hydrogen bonding) might play a 
vital role in the interactions between some palladium complexes and DNA.37  Results 
published by Al-Allaf and Rashan38 indicate that most of the trans-palladium 
complexes (representative structure shown in Fig. 1.5-C) show better activity than 
the cis-platinum and cis-palladium isomers.29  The trans-palladium complexes were 
also found to show activities equal to, or superior than, those of cisplatin, carboplatin 
and oxaliplatin in in vitro studies.  The cyclopalladated complex [Pd2(C2,N-S(-
)dmpa)2(µ-dppe)Cl2] (Fig. 1.5-D) also shows inhibitory in vitro activity at low 
concentrations (<1.25 µM) and shows good in vivo activity, delaying tumour growth 
and prolonging animal survival.29  
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N
N N
N
R
R
RR Pd
R =
OCH2CO2H
OCH2CO2H
109
 
 
Fig. 1.6: Structure of the 109Pd-porphyrin complex synthesized by Chakraborty et al.39 
 
The promising results shown by palladium complexes have also attracted the 
attention of radiopharmaceutical researchers. In 2007, a 109Pd-porphyrin complex 
(Fig. 1.6) was synthesized by Chakraborty et al.39 for preliminary biological 
evaluation for possible use in targeted tumour therapy. Results of the biodistribution 
studies in Swiss mice bearing fibrosarcoma tumours reveal good tumour uptake 
within 30 minutes post-injection and it remains almost constant 24 hours post-
injection. The high tumour/blood and tumour/muscle ratios exhibited by the 
radiolabelled palladium porphyrin complex indicate its potential for use in targeted 
tumour therapy.39 
 
Indeed, the current focus in drug design is the development of drugs that can be 
transported through the cellular membrane, survive in the cell, and if possible, 
excrete from the body with minimal side effects. In this process, metal coordination 
and hydrogen bonding will be key factors and palladium complexes, especially those 
kinetically more stable in biological media, arise as great candidates. 
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1.3.4. Gallium-based complexes 
 
Gallium has tumour-seeking and antineoplastic properties that have been recognised 
for over 30 years.16 Gallium is the second metal ion, after platinum, to be used in 
cancer treatment. Its activities are numerous and various.  Gallium has been known 
to modify the three-dimensional structure of deoxyribonucleic acids (DNA), and 
inhibits its synthesis, modulates protein synthesis and inhibits the activity of a 
number of enzymes, such as ATPases, DNA polymerases, ribonucleotide reductase 
and tyrosine-specific phosphatase. Gallium also alters plasma membrane 
permeability and mitochondrial functions.15  
 
It is generally agreed that the critical cellular target of gallium is the enzyme 
ribonucleotide reductase, which catalyses the reduction of ribonucleotides to 
deoxyribonucleotides required for DNA synthesis and has long been recognised as a 
suitable target for cancer chemotherapy. The activity of this enzyme is inhibited by 
binding of gallium to the iron site of the R2 subunit and the resulting destabilisation of 
the tyrosyl radical essential for enzymatic activity. This results in the depletion of 
deoxynucleoside diphosphate (dNDP) pools, impairs DNA synthesis, cell cycle 
perturbations and apoptosis through the mitochondrial pathway involving activation 
of the proapoptotic factor Bax and caspase-3 (Fig. 1.7). Caspase-3 is a protein that 
is a member of the cysteine-aspartic acid protease (caspase) family and is known as 
an apoptosis-related cysteine peptidase.40 
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Fig.1.7: Schematic representation of the mode of action of gallium compounds.40 
 
The safety and activity of gallium salts, such as gallium nitrate, have been 
extensively studied in clinical trials since 1975. Gallium nitrate has proved to be an 
effective drug for the treatment of malignancy, but its unfavourable pharmacokinetic 
properties prevent its use in systematic chemotherapy of cancer patients.  Parenteral 
administration is associated with a low therapeutic index due to renal toxicity, and 
oral administration is inefficient due to insufficient intestinal absorption. The 
development of tumour-inhibiting gallium complexes have been pursued as a 
strategy to overcome the limitations faced with gallium salts.16 
 
It has been shown that improved bioavailability compared to gallium chloride and 
sufficient plasma concentration can easily be reached with tris(8-
quinolinolato)gallium(III), KP46 (Fig. 1.8).5  This compound exhibits better 
antiproliferative properties and superior capacity for apoptosis induction in vitro when 
compared to gallium nitrate.5 Of a series of gallium complexes studied, KP46 was 
selected for further development and has successfully completed phase I clinical 
trials.5,41 
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Fig. 1.8: Structure of tris(8-quinolinolato)gallium(III), KP46. 
 
Gallium radioisotopes, especially 67Ga and 68Ga, have long been of interest in the 
design of radiopharmaceuticals.42 The interesting physical properties and availability 
of this radioisotope makes it an interesting nuclide for research in 
radiopharmaceuticals.43 It was found that the radioisotope 67Ga shows some promise 
in the study of bone cancer as compounds of this isotope are absorbed by the 
cancer deposits in the bone.  
 
Gallium-67 citrate (67Ga-citrate) has been found to accumulate in certain viable 
primary and metastatic tumours, as well as focal sites of infection, which makes it an 
ideal imaging agent. The 67Ga radioisotopes accumulate in the lysosomes, being 
bound to intracellular protein. The empirical formula of gallium-67 citrate is believed 
to be 67Ga(citrate-(3-)) with three water molecules presumably filling the remaining 
coordination sites (Fig. 1.9). The citrate, however, is a weak chelator ligand. As soon 
as 67Ga-citrate is injected into the bloodstream the 67Ga is transchelated to 
transferrin. The transchelation of Ga(III) complexes in vivo by transferrin requires 
that kinetically inert complexes of Ga(III) be developed for radiopharmaceutical 
applications. Thus, there has been increased research into developing new gallium-
based radiopharmaceuticals for tumour therapy/imaging.44  
 
O
O
O
O
O
Ga O
H2O
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Fig. 1.9: The proposed structure of 67Ga-citrate. 
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One of the best known chelators used for gallium (radioactive and non-radioactive) is 
the macrocyclic 1,4,7,10-tetraazadodecane-1,4,7,10-tetraacetic acid (DOTA) ligand 
(Fig. 1.10). Ga(DOTA)- is sufficiently stable to be used in clinical practice and 
several derivatives of DOTA have been reported.45 
 
N
N
N
N
OHOOHO
OHO HO O 
 
Fig. 1.10: Structural representation of the 1,4,7,10-tetraazadodecane-1,4,7,10-tetraacetic acid 
(DOTA) ligand. 
 
Orvig and co-workers46 have also reported novel bifunctional chelate alternatives to 
DOTA derivatives for application of radioisotopes of gallium to diagnostic nuclear 
medicine. In a 2 hour competition experiment against human apo-transferrin, 
[67Ga(dedpa)]+ (Fig. 1.11) showed no chemical instability. The stability of this chelate 
and its derivatives is higher than that of the DOTA ligands. Biodistribution studies 
also confirm the stability of the complexes measured in vitro with general clearance, 
rendering these frameworks a good basis for development of new gallium 
bioconjugates. 
 
HN NH
N N
O O
O O
Ga67
 
Fig. 1.11: Structure of [67Ga(dedpa)]+ synthesized by Orvig and co-workers. 
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Previous work has shown that metal salts and other metal complexes present their 
own problems in terms of drug resistance and other significant side effects.  
However, at the same time there has been an emergence of studies of new 
structural types of metal complexes with promising biological activity and with the 
ability to circumvent these issues.29 Under this focus or drive to design new 
coordination compounds with anticancer/imaging properties, decreased toxicity and 
establishment of new biological targets is just the type of impetus to advance the 
bioinorganic chemistry of ruthenium, palladium and gallium complexes.29 Literature 
has also shown, however, that these metals have to be bound to the right type of 
organic ligand, and in recent years there have been promising developments in the 
use of thiosemicarbazones (section 1.4.) and nanomolecules such as dendrimers 
(section 1.5.) as possible anti-cancer and imaging agents. 
 
1.4. Thiosemicarbazones 
 
Thiosemicarbazones belong to a large group of thiourea derivatives whose biological 
activity is a function of its parent aldehyde or ketone moiety.38,40  
Thiosemicarbazones are molecules of interest in coordination chemistry due to their 
pharmacological properties, which include antiparasital, antibacterial and antitumour 
activities.8,16,47-49 Studies on structure-activity relationships of thiosemicarbazones 
have suggested that the antitumour activities of thiosemicarbazones are increased 
by their ability to form chelates with metal ions.16,49  Petering and co-workers50 first 
demonstrated that some heterocyclic carboxaldehyde thiosemicarbazones are 
activated by chelation to iron or copper.16,51 The same effect of activation by 
chelation has been observed with 2-acetylpyridine thiosemicarbazones8,52 and some 
other heterocyclic thiosemicarbazones53 as well.  Thiosemicarbazones (Fig. 1.12) 
usually bind to metal ions either in the neutral thione form (i(a)) or in the thiolate form 
(ii) as bidentate N,S-donor ligands.54 When complexation occurs it is usually via the 
dissociation of the acidic proton on the sulphur atom of the thiol (i(b)), which results 
in the formation of a five-membered chelate ring (iii).55 
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Fig.1.12: Thiosemicarbazone structures (i(a) – thione form, i(b) – thiol form, ii – thiolate form, iii – 
complexation of thiolate form with metal cation). 
 
It is well known that the imine (C=N) and thiourea moieties can form stable 
complexes with various metal ions.56 The introduction of a third potential donor atom 
to the thiosemicarbazone ligand would form a tridentate ligand that should increase 
its versatility and flexibility in coordination behaviour.56 
 
α-N-Heterocyclic thiosemicarbazones are known to be amongst the most potent 
inhibitors of ribonucleotide reductase and it has long been generally assumed that 
this enzyme, in particular its iron-containing R-2 subunit, is the critical target site.57,58  
It has also been assumed that the iron chelates formed by biotransformation are the 
actual active species. However, there have been more recent studies that question 
the universal validity of these assumptions and suggest that there is an involvement 
of inhibition of topoisomerase II in some of these compounds and their metal 
complexes.53,59  It is proposed that the thiosemicarbazones could stabilize cleavable 
complexes formed by topoisomerase II and DNA leading to apoptosis47, a natural 
process of cell destruction in certain cells, induced either by stimulus such as 
irradiation or toxic drugs, that are genetically programmed to have a limited life span 
or that are damaged. The stabilizing effect is attributed to be mainly due to the 
alkylation of thiol residues on the topoisomerase II-DNA complex.47,60  
Topoisomerase is a nuclear enzyme that adjusts the topological state of DNA by 
breaking and resealing DNA strands resulting in alterations in the linking number.60  
ii iii 
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Topoisomerase II regulates the topological structure of DNA by transient breaking 
and rejoining of double-stranded DNA in an ATP-dependent manner.60 
 
Since 1990, the chemistry of transition metal and non-transition metal complexes of 
thiosemicarbazones has received considerable attention, largely due to their 
bioinorganic relevance.61,62 Even though the combination of a central metal ion and a 
ligand, which are both supposed to target the same molecular target, seems like a 
worthwhile task, there has been a lack of research into the biological activity of 
gallium thiosemicarbazone complexes. 
 
1.4.1. Gallium (III) complexed to thiosemicarbazones 
 
The gallium complex bis(2-acetylpyridine-4,4-dimethyl-3-thiosemicarbazonato-
N,N,S)gallium(III) tetrachlorogallate(III) (KP1089, Fig. 1.13-E) was the first of the α-
N-heterocyclic thiosemicarbazone complexes to be assayed for antineoplastic 
activity in human tumour cell lines. The in vitro activity of KP1089 was found to be 
the highest among the gallium complexes tested, which also provides some 
evidence implying that the combination of a metal ion and a ligand which are both 
pharmaceutically active and aimed at attacking the same molecular target displays 
optimal efficacy.63 
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Fig. 1.13: Structures of KP1089 (E) and [67Ga]-2-acetylpyridine-4,4-dimethylthiosemicarbazone (F –
structure proposed by Haghighi-Moghadam et al.49). 
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Gallium complexes of different 2-acetylpyridine thiosemicarbazone derivatives have 
previously been reported42, although without biological evaluation.16 It has also been 
suggested that [67Ga]-2-acetylpyridine-4,4-dimethylthiosemicarbazone (Fig. 1.13-F, 
the proposed structure) could possibly act as a SPECT tracer with a long half-life for 
tumour imaging applications (i.e. a potential radiopharmaceutical).64 
 
1.5. Dendrimers/Metallodendrimers 
 
The basis of the dendrimer structure consists of a core encased within concentric 
shells formed by covalently linked branches, resulting in a nearly-perfect three-
dimensional geometric pattern.65,66  Dendrimers serve as the central platform for a 
new generation of nanodevices that are designed to be multifunctional diagnostic 
and treatment tools.65 There are many variations of this simple structure that can be 
produced by following a number of proven synthetic approaches.65 The addition of 
another shell corresponds to an increase in the generation (G) number, which 
coincides with an increase in the diameter and a multiplied increase in the number of 
branches (Fig. 1.14).65 The average size and structure of a dendrimer within a batch 
can be controlled by precisely reproducing the subsequent expansion of the 
branching network.65 
 
 
 
Fig. 1.14: A representation of the different generations of dendrimers. 
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Dendrimers can be synthesized via two major routes: (a) the divergent route and (b) 
the convergent route (Fig. 1.15), which differs in their direction of synthesis; either 
outward from the core or inwardly toward the core, respectively. 
 
 
Fig. 1.15: The two major synthetic routes: Divergent (top) and convergent (bottom). 
The divergent method was first introduced by Tomalia and co-workers67 in the 
1980’s, where they synthesized poly(amidoamine), PAMAM, dendrimers by the 
growth of branches extending from the core site to the periphery.66,67 The convergent 
method was first established by Hawker and Frechet68 in 1990, whereby the 
dendrimer surfaces were first synthesized by gradually linking surface unit 
monomers together.66 When the growing surface wedges are large enough, several 
are attached to a suitable core to give a complete dendrimer.66 
Furthermore, there are many and various properties of dendrimers that include: 
 nanoscale sizes that have similar dimensions to important bio-building blocks 
(e.g. Proteins, DNA).   
 number of terminal surface groups that are suitable for bio-conjugation of 
drugs, signaling groups, targeting moieties or biocompatibility groups, and can 
be designed with functional groups to augment or resist trans-cellular, 
epithelial or vascular biopermeability. The surface groups can also be 
modified to optimize biodistribution. 
 an interior void space that can be used to encapsulate small molecule drugs, 
metals or imaging moieties.  Encapsulation in that void space reduces the 
drug toxicity and facilitates controlled release.66,69 
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Terminal branches of reactive dendrimers will often be capped to neutralize 
toxicity.65,66,70 The size of dendrimers, which is closely associated with the generation 
(G) number, influences not only the cytotoxicity of the dendrimer but also its solubility 
in aqueous solution and its encapsulation stability.65,71,72 The extent of the terminal 
surface and interior functionalities provided by the unique hyper-branched structure 
of the dendrimers has been researched extensively. There are several studies that 
have shown that a variety of molecules have retained their function while conjugated 
to the surface of a dendrimer.73-76 The ability to modify the dendrimer to fit very 
specific needs makes dendrimers an exciting and promising subject of research.65 
Targeting agents, chemotherapeutic drugs and fluorescent markers are but a few of 
the functional groups that have been conjugated to the branches of a dendrimer to 
change the function of the nanomolecule.65 Exploiting the multifunctional capabilities 
of the dendrimer allows for the approach of a problem from many perspectives while 
still using the same concept.65 
 
Fig. 1.16: Structural representation of metallodendrimers with emphasis on different locations of metal 
fragments within the dendritic frame at the center (nodal core), branching points and periphery, 
respectively.77 
While the majority of dendrimers reported thus far are organic in nature, there is a 
rising interest in dendrimers containing transition metal ions.77-81 Metallodendrimers 
are particularly interesting as the metallic moieties can easily be integrated into 
different parts of the dendritic structure, which includes the nodal core, branching 
points and periphery (Fig. 1.16),79 and their specific properties (e.g. redox, 
electronic, optic, magnetic, etc.) can be modulated accordingly by collective effects 
through the hierarchization (generations) and compartmentalization (alternated or 
segmented constitutive lobes) of the dendritic structure and topology.77 
Enhancement of magnetic resonance imaging (MRI) diagnostic sensitivity can be 
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achieved through the utilization of dendrimer-based contrast agents.65 Contrast 
agents are compounds used to improve the visibility of internal bodily structures in 
an X-ray image or a MRI. Targeted delivery of contrast agents can improve the 
contrast between cancerous tissue and healthy tissue.65 Targeted methods have 
been proven to promote nanodevice, such as a dendrimer, internalization specifically 
by cancer tissue.65 There are some reports that have shown that in vivo research 
into the incorporation of gadolinium into different types of dendrimer-based 
nanomolecules can produce quality contrast agents for multiple applications.82-86 The 
first dendrimer-based contrast agents were developed by Wiener et al.86 in the early 
1990’s. They created a novel contrast agent by binding Gadolinium chelates to 
poly(amidoamine), PAMAM, dendrimers (Fig. 1.17). Wiener et al.86 discovered that 
the attachment of Gadolinium to the dendrimer actually accelerates the longitudinal 
relaxation more than Gadolinium on its own.  It has been suggested that although 
the dendrimer alone has little effect on relaxation rates, the high molecular weight of 
the dendrimer plays an important role in altering the properties of Gadolinium.87 
 
Fig. 1.17: Structure of a gadolinium(III) poly(amidoamine), PAMAM, dendrimer. 
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Improvements to this novel contrast agent have since been made by many 
researchers, most notably by Kobayashi and co-workers82-84 from Kyoto University in 
Japan. An increased size and molecular weight of the nanoparticle facilitates 
extended presence of the contrast agent in the blood.82 The large size of the 
dendrimer chelate also helps to ensure that the contrast agent does not diffuse out of 
the intratumoural vessels but into the tumoural tissues.82 These properties are 
beneficial when monitoring changes in tumour vasculature over periods of time.82 In 
this respect tumours can specifically be targeted by employing the greatest possible 
advantages of the ‘enhanced permeability and retention’ (EPR) effect displayed by 
dendrimers. 
 
1.5.1. The ‘enhanced permeability and retention’ (EPR) effect 
 
The ‘enhanced permeability and retention’ (EPR) effect (Fig. 1.18) can be defined as 
being the accumulation of macromolecules at the tumour site due to an increase in 
blood vessel permeability in diseased cells compared to normal cells.88,89 The normal 
endothelial layer surrounding the blood vessels feeding healthy tissues restricts the 
size of molecules that can diffuse from the blood, whereas the endothelial layer of 
blood vessels in diseased tissues is more porous providing access to the 
surrounding tissue.88 Furthermore, diseased tissue does not usually have a 
lymphatic drainage system so once macromolecules have entered the tissue they 
are retained.88 
 
 
 
Fig. 1.18: The EPR effect of polymer-drug conjugates on a tumour. 
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In order to exploit the size selective uptake of drugs into tumour cells effectively, 
large compounds are required, and in recent years, dendrimers/metallodendrimers 
have found potential as molecular tools in biological applications,88,90 especially as 
nano-carriers,91 chemotherapeutics92 and diagnostic/contrast agents93 for use in 
imaging. 
 
1.5.2. Metallodendrimers used in Imaging 
There is a growing interest in dendrimers as delivery systems for small molecules 
and radiation contrast agents.94 Imaging modalities can be used in oncology to 
diagnose, locate, stage, plan treatment and potentially to find recurrence. Computed 
tomography (CT) and MRI are two standard methods of imaging associated with 
cancer diagnoses. Gadolinium paramagnetic contrast agents for MRI have been 
complexed with dendrimer molecules over the last two decades for contrast 
enhancement, improved clearance characteristics and for potential targeting.95 Gd-
labelled PAMAM dendrimers have been used for visualizing both tumour vasculature 
and lymphatic involvement.  Changes in tumour permeability were visualized by MRI 
using generation 8 Gd-PAMAM contrast agents after a single large dose of radiation 
treatment.93,96 Gd-labelled generation 6 PAMAM dendrimers were also shown to 
accumulate in the sentinel lymph nodes (Fig. 1.19), which are routinely imaged 
before surgery for breast cancer and melanoma.97 
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Fig. 1.19: Visualization of sentinel lymph node via gadolinium-labelled PAMAM dendrimers. Rapid 
and enhanced visualization of the sentinel lymph node using magnetic resonance lymphangiography 
is achieved by optimizing the size of gadolinium-labelled PAMAM  
contrast agents.93 
Similarly to Gd-dendrimer conjugates for MRI, iodinated contrast agents used for CT 
could benefit from dendrimer conjugation as it provides improved retention times and 
the potential for targeted delivery.93 With the growing interest in dendrimers as 
delivery vehicles, techniques for studying these polymers in biological systems are 
needed. The labelling of dendrimers with radioisotopes coupled with radiochemical 
detection is a very effective method for studying the uptake and fate of compounds in 
vivo.94 There has been a few reports describing the incorporation of radioisotopes 
into dendrimer structures,94,98 but overall there has been a lack of research into the 
synthesis and biological activity of radiolabelled dendrimers as potential 
radiopharmaceuticals. 
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1.6. General Conclusions 
There has been a lot of interest shown in the chemistry of transition metal and non-
transition metal complexes of thiosemicarbazones. This can mainly be attributed to 
the thiosemicarbazone ligand’s variable donor properties, structural diversity and 
well established biological applications. It should be noted that, while there are quite 
a number of reports on the biological activities of gallium(III) thiosemicarbazones, 
reports on studies of radiolabelled gallium(III) thiosemicarbazones, especially as 
imaging agents, are still quite  limited. 
There has also been a large number of reports on dendrimers. However, transition 
metal containing dendrimers have risen as a topic of interest.  In recent years 
metallodendrimers have shown potential in biological applications, especially as 
diagnostic/ contrast agents for use in imaging. 
 
1.7. Aims and Objectives  
 
1.7.1. Aims 
 
The general aims of this research project are to synthesize and characterize various 
mononuclear, and possibly binuclear, radiolabelled gallium thiosemicarbazones, 
evaluate their radiolabelling properties and study their radiobiology (i.e. in vitro cell 
uptake studies). 
 
The aims are also to synthesize α-diimine ligands containing zero (G0) and first 
generation (G1) dendritic wedges, and to complex these ligands with palladium.  
These ligands will form part of a preliminary study where they will be tested for their 
radiolabelling ability with 109Pd. 
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1.7.2. Objectives 
The objectives of this research project are to: 
1.7.2.1. Synthesize and characterize a series of thiosemicarbazone ligands as 
outlined in equation (1.1). 
Ar R1
O
+ H2N
N
H
R2
S
Ar
R1
N
H
N R2
S
R1 = H, CH3
R2 = NH2, N(CH3)2  
1.7.2.2. Synthesize radiolabelled gallium(III) thiosemicarbazones using ligands 
synthesized in equation (1.1). 
1.7.2.3. Perform radiochemical stability studies of successfully radiolabelled 
gallium(III) thiosemicarbazones. 
1.7.2.4. Evaluate a few of the radiolabelled gallium(III) thiosemicarbazones for their 
in vitro cell uptake abilities. 
1.7.2.5. Synthesize and characterize the α-diimine core, dendritic (G0 and G1) 
wedges and subsequently the dendritic (G0 and G1) ligands. 
1.7.2.6. Synthesize and characterize new dendritic complexes as in equation (1.2) 
using PdCl2(COD). 
…Eq. (1.1) 
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N N ORwedgeRwedgeO
Br
Br-Rwedge =
Br
OO
G0
G1
Pd
Cl Cl
N N ORwedgeRwedgeO
PdCl2(COD)/CH2Cl
O OCH3
O OCH3 OCH3O
/24 hrs, rt.
 
1.7.2.7. Test the radiolabelling ability of polyaryl(ether) dendrimers (G0 and G1) with 
109Pd. 
 
 
 
 
 
 
 
 
…Eq. (1.2) 
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Chapter 2: 
 
Synthesis and characterization of 
monothiosemicarbazone and dithiosemicarbazone 
ligands 
 
2.1. Introduction 
 
Thiosemicarbazones have been known to exhibit various biological activities and 
have thus attracted considerable attention.1-4  Thiosemicarbazones belong to a large 
group of thiourea derivatives and they have been known for their donor ligand 
ability.1,5-8  Thiosemicarbazone ligands can be synthesized via the condensation of 
an aldehyde or ketone with thiosemicarbazide.9  A thiosemicarbazone ligand has 
different R (R1-R4), alkyl or aryl, substituents (Fig. 2.1), thus various derivatives of 
the ligand can be formed.9 
 
R1
R2
N3
H
2N
S
N1
R3
R4
thiourea moiety
 
 
Fig. 2.1: A structural representation of a thiosemicarbazone ligand. 
 
 
A thiosemicarbazone ligand based on an aldehyde has a hydrogen atom as the R2 
substituent, whereas the ligand based on a ketone may have different alkyl or aryl 
groups as the R2 substituent.  A thiosemicarbazone based on a ketone may at times 
have R1 and R2 substituents that are the same.  The R1 substituent may be alkyl, aryl 
or heteroaromatic.  The heteroaromatic group provides the nitrogen, oxygen or 
sulphur that acts as the third donor atom in coordination of a metal to the ligand.  
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The substituents on the N1 nitrogen (i.e. R3 and R4) may be hydrogens, alkyls, aryls 
or part of a cyclic group.9 
 
Dithiosemicarbazone ligands are dimeric structures that consist of two 
thiosemicarbazone moieties.  These thiosemicarbazone moieties are connected via 
their thioamide nitrogen atoms to an aliphatic or aromatic spacer (Fig. 2.2).10 
 
R2
R1 N
H
N
S
H
N
R2
R1N
N
H
S
N
H
alkyl or aromatic spacer  
 
Fig. 2.2: A structural representation of a dithiosemicarbazone ligand. 
 
Thiosemicarbazones are interesting molecules as biologically active compounds, as 
have been shown in literature studies.1-9  It would thus also be interesting to study 
the radiolabelling ability of a series of these ligands as their respective radiolabelled 
complexes could possibly act as imaging agents. This study should prove interesting 
as similar studies on the radiolabelling abilities of thiosemicarbazones as a function 
of their chemical structures have, to this author’s knowledge, not previously been 
reported in literature. 
 
2.2. Monothiosemicarbazone ligands 
 
2.2.1. Synthesis of monothiosemicarbazones 
 
The monothiosemicarbazones (Table 2.1, 1-18 and 20-21) were prepared by either 
dissolving the respective thiosemicarbazide in distilled water or by having the 
respective thiosemicarbazide suspended in ethanol and adding an ethanolic solution 
of the aldehyde/ketone to the thiosemicarbazide solution/suspension.  The reaction 
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is represented by equation (2.1). The mixture was reacted at room temperature or 
using temperatures ranging between 60-100C.   
 
H2N
N
H
S
R2
+
Ar
O
R1
Ar N
H
N
S
R2
R1
H2O
 
 
Table 2.1: The series of monothiosemicarbazone ligands (1-18, 20 and 21) that were 
synthesized. 
Ar 
 
(R1; R2) 
N  
(R1; R2) 
O  
(R1; R2) 
N
H  
(R1; R2) 
N
 
(R1; R2) 
L
ig
a
n
d
s
 
1 
(H; NH2) 
4 
(H; NH2) 
2 
(H; NH2) 
9 
(CH3; NH2) 
5 
(H; NH2) 
3 
(H; N(CH3)2) 
17 
(H; N(CH3)2) 
7 
(CH3; NH2) 
12 
(CH3; N(CH3)2) 
6 
(CH3; NH2) 
8 
(CH3; NH2) 
18 
(CH3; N(CH3)2) 
15 
(H; N(CH3)2) 
13 
(H; N(CH3)2) 
10 
(CH3; N(CH3)2) 
  16 
(CH3; N(CH3)2) 
14 
(H; NH2) 
11 
(H; N(CH3)2) 
    20 
(H; NHPh) 
    21 
(CH3; NHPh) 
 
 
The synthesis of the N,N-dimethylthiosemicarbazone ligands produced four new 
ligands (12, 16, 17 and 18) as part of this study. Acetic acid was used in the 
synthesis of the ligands where a methyl (R1 = CH3) was attached to the imine bond 
due to the fact that the ketones are generally less reactive than their respective 
…Eq. (2.1) 
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aldehydes.  This is due to the alkyl chain of a ketone having an inductive effect that 
causes the carbon (in the carbonyl group) to be less electrophilic, thus being less 
reactive when compared to the aldehyde.  The synthesis of the 
monothiosemicarbazone ligands proceeds via a Schiff-base condensation reaction 
mechanism (Scheme 2.1) whereby an imine bond is formed and water is produced 
as a by-product. The synthesis of the thiosemicarbazones produced white or orange-
yellow powders in low to good yields (33% – 87%).  The monothiosemicarbazone 
ligands are soluble in ethanol, methanol and DMSO. The N,N-
dimethylthiosemicarbazone ligands are also soluble in dichloromethane and 
chloroform. The ligands were characterized using 1H-NMR and IR spectroscopy, as 
well as elemental analysis. 
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2.2.2. NMR spectra of monothiosemicarbazones 
 
2.2.2.1. 1H-NMR spectra 
 
The 1H-NMR spectra of the thiosemicarbazone ligands (non-substituted terminal 
amines 1, 2, 4-9 and 14) show two peaks between 7.61-8.38 ppm accounting for the 
Scheme 2.1: Mechanism of a Schiff-base condensation 
reaction. 
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protons on the primary/terminal amine (-NH2).  A peak is seen at 7.61-8.13 ppm 
whereas the other peak occurs slightly further downfield at 8.19-8.38 ppm.  This type 
of splitting was also observed by Dilovic et al.1 in the synthesis of a salicylaldehyde 
thiosemicarbazone and reported by Lobana et al.9 in a review on thiosemicarbazone 
derivatives of metals.  The reason for this splitting could be due to the lone pair of 
electrons on the amine nitrogen donating back to form a double bond with the 
electrophilic carbon, which would cause the C=S bond to push electrons onto the 
sulphur to give it a negative charge (Fig. 2.3).9 There would thus be no free rotation 
about the carbon-nitrogen bond, which means the amine protons are in different 
environments.  This would thus give two separate peaks in the 1H-NMR spectrum. 
 
S
N
H
H
S
N
H
H
 
Fig. 2.3: Resonance occurring at the amine terminal of a thiosemicarbazone. 
 
The thiosemicarbazone ligands (non-substituted terminal amines) where R1 = H (1, 
2, 4, 5 and 14) shows a singlet peak occurring just above 8.00 ppm accounting for 
the proton on the imine carbon (as can be seen in Fig. 2.4).  There is, however, a 
singlet peak appearing at 2.33-2.41 ppm in the spectrum of the thiosemicarbazone 
(where R1 = CH3, 6-9) that accounts for the methyl group on the imine bond. The 
aromatic/heteroaromatic protons are found to occur between 6.04-8.95 ppm for all 
ligands. 
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Fig. 2.4: 1H-NMR (in DMSO-d6) spectrum of 2-formylpyridine thiosemicarbazone, 5 (representative 
spectrum). 
 
The hydrazinic protons (-NH-) of the thiosemicarbazone ligands are found to be the 
furthest downfield of all the proton peaks (Table 2.2, on the next page).  This is 
partially due to the fact that the proton is directly bonded to a nitrogen that is situated 
between an imine bond (C=N) and a C=S group, all of which are significant electron-
withdrawing groups. Another reason for the downfield shift of the hydrazinic proton 
was reported by Mendes et al.11 and Rebolledo et al.12 Both reported that the 
downfield shift of the hydrazinic proton in a thiosemicarbazone could be due to 
hydrogen bonding that occurs between the proton and an oxygen of the deuterated 
dimethyl sulfoxide solvent. However, the hydrazinic proton still appears downfield 
when the sample is submitted in deuterated chloroform. The hydrazinic proton of the 
ligands where R1 = CH3 appears more upfield (10.21-10.24 ppm) when compared to 
the hydrazinic proton of the ligands where R1 = H (11.41-11.56 ppm). This could 
possibly be due to the inductive effect exerted on the ligand by the methyl group 
bonded to the imine. This inductive effect provides some shielding of the hydrazinic 
proton when compared to the ligands where a proton is bonded to the imine moiety 
(i.e. R1 = H). There is also no evidence of both E and Z isomers being present. 
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Table 2.2: Summary of 1H-NMR shifts (ppm) of thiosemicarbazone ligands (non-substituted 
terminal amines) in DMSO-d6. 
Compound Ar R -CH=N- -CH3 -NH2 -NH- 
1 Benzene H 8.09 — 7.98/8.19 11.42 
2 2-furan H 8.00 — 7.61/8.19 11.41 
4 3-pyridine H 8.10 — 8.26 11.56 
5 2-pyridine H 8.11 — 8.07/8.22 11.55 
6 2-pyridine CH3 — 2.41 8.13/8.38 10.29 
7 2-furan CH3 — 2.26 7.69/8.24 10.24 
8 Benzene CH3 — 2.33 7.95/8.26 10.21 
9 2-pyrrole CH3 — 2.15 8.08/8.21 11.35 
14 2-pyrrole H 7.80 — 7.85/7.95 11.28 
 
 
The 1H-NMR spectrum (in CDCl3) of the 2-acetylpyridine-4,4-
dimethylthiosemicarbazone ligand, 10, shows that the product contains a mixture of 
isomers (possibly a Z, E and thiol form), as was reported by J. Chan et al.13 The 1H-
NMR spectrum of ligand 10 displays broad peaks when submitted in DMSO-d6.  
There are peaks occurring between 2.37-2.61 ppm that account for the protons on 
the methyl group of each of the isomers. The methyls attached to the terminal 
(tertiary) nitrogen of the isomers occur as a multiplet at 3.48 ppm.  The protons on 
the pyridine ring of the isomers appear between 7.25-8.73 ppm, occurring mostly as 
multiplets. Interestingly, the hydrazinic proton of one of the isomers occurs at 8.46 
ppm as a broad singlet, whereas the hydrazinic proton of the other isomers occurred 
further downfield at 14.82 and 15.51 ppm.  The reason for this is still not quite 
understood. 
 
The other N,N-dimethylthiosemicarbazones (3, 10-13 and 15-18) show the presence 
of just one set of peaks, i.e. one isomer. The aromatic protons are found to appear 
between 6.39-8.63 ppm for the ligands. The dimethyl protons appear more upfield at 
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3.36-3.37 ppm for the pyrrole derivatives (12 and 13), 3.43-3.48 ppm for the pyridine 
derivatives (10, 11, 17 and 18), 3.29 ppm for the benzyl derivative (3) and 3.27-3.39 
ppm for the furan derivatives (15 and 16). The peak accounting for the proton on the 
imine bond of ligands 11 (Fig. 2.5) and 13 appears between the aromatic peaks at 
7.50 and 7.20 ppm, respectively. The peak for the proton on the imine bond of 15 
occurs slightly more downfield at 8.08 ppm, however, the ligand was run in 
deuterated-DMSO.  The spectrum of 15 in CDCl3 displays very broad peaks.  The 
peak accounting for the imine proton of the N,N-dimethylthiosemicarbazones 
appears more upfield when compared to the imine proton peak of the 
thiosemicarbazones with a free terminal amine. The corresponding protons on the 
methyl bonded to the imine moiety of 12, 16 and 18 appear further upfield at 2.27-
2.53 ppm, which corresponds to similar peaks found for 10. 
 
 
   
Fig. 2.5: 1H-NMR (in CDCl3) spectrum of 2-formylpyridine-4,4-dimethylthiosemicarbazone, 11 
(representative spectrum). 
 
The aromatic/heteroaromatic protons of the N,N-dimethylthiosemicarbazone ligands 
are found to occur in similar regions as is seen for the thiosemicarbazone ligands 
with the non-substituted terminal amines.  The hydrazinic protons of the N,N-
dimethylthiosemicarbazone ligands are not as consistent in their peak shifts as is 
seen for the thiosemicarbazone ligands with the non-substituted terminal amines 
(Table 2.3).  The hydrazinic protons are found to appear between 7.03-15.51 ppm.  
Unlike the non-substituted terminal amine thiosemicarbazone ligands, the N,N-
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dimethylthiosemicarbazones do not always have the hydrazinic proton of the ligands 
where R1 = H slightly more downfield when compared to the hydrazinic protons of 
the ligands where R1 = CH3. 
 
Table 2.3: Summary of 1H-NMR shifts (ppm) of N,N-dimethylthiosemicarbazone ligands in 
CDCl3 (unless otherwise stated). 
Compound Ar R
1
 -CH=N- -CH3 -N(CH3)2 -NH- 
3
a
 Benzene H 8.17 — 3.29 10.81 
10 2-pyridine CH3 — 
2.65/2.41 
/2.55 
3.48 8.46/14.82 
/15.51 
11 2-pyridine H 7.50 — 3.48 15.10 
12 2-pyrrole CH3 — 2.53 3.36 12.97 
13 2-pyrrole H 7.15 — 3.37 12.90 
15
a
 2-furan H 8.08 — 3.27 10.78 
16 2-furan CH3 — 2.46 3.39 7.03 
17 3-pyridine H 7.70 — 3.45 8.94 
18 3-pyridine CH3 — 2.27 3.43 8.39 
a Compound was analyzed in DMSO-d6. 
 
The aromatic (pyridyl and phenyl) protons of the 2-pyridine-4-
phenylthiosemicarbazones (formyl, 20, and acetyl, 21) appear in similar regions to 
each other, i.e. 7.22-8.60 ppm, and to the thiosemicarbazones previously mentioned 
in this chapter.  The hydrazinic proton of the R1 = H derivative is more downfield 
compared to the R1 = CH3 derivative, which is also seen in the previously mentioned 
2-pyridinethiosemicarbazones.  The proton on the terminal amine (-NH-Ph) occurs 
just above 10 ppm for both 4-phenylthiosemicarbazone derivatives (Table 2.4).  The 
proton on the imine bond of 20 appears at 8.22 ppm, which is in a similar region to 
what has previously been seen with other 2-formylpyridinethiosemicarbazone 
derivatives (5 and 11).  The peak accounting for the protons of the methyl group 
bonded to the imine moiety of 21 appears at 3.21 ppm.  This is slightly more 
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downfield when compared to ligands 6 and 10 (2-acetylpyridinethiosemicarabzone 
derivatives). 
 
Table 2.4: Summary of 1H-NMR shifts (ppm) of 4-phenylthiosemicarbazone ligands in 
DMSO-d6. 
Compound Ar R -CH=N- -CH3 -NH-Ph -NH- 
20 2-pyridine H 8.22 — 10.17 11.91 
21 2-pyridine CH3 — 3.21 10.12 10.55 
 
 
2.2.2.2. 13C{1H}-NMR spectra 
 
13C{1H}-NMR spectroscopy was also used in the characterization of newly 
synthesized ligands (12, 16-18).  The imine carbon of the ligands appears at 135.5-
152.2 ppm (Table 2.5), which is slightly downfield when compared to the 
heteroaromatic carbon peaks (111.4-150.1 ppm).  The individual heteroaromatic 
carbon peaks are assigned using Heteronuclear Single Quantum Correlation 
(HSQC).  The thione carbon, at the center of the thiourea moiety, is found to be the 
most downfield at just above 180 ppm (with the exception of 16, which showed a 
peak accounting for the thione carbon at 146.0 ppm).  This is most likely due to the 
fact that carbon is surrounded by electron withdrawing groups (nitrogen and sulfur, 
with electronegativity of 3.04 and 2.58, respectively). 
 
Table 2.5: Summary of 13C-NMR shifts (ppm) of newly synthesized 4,4-
dimethylthiosemicarbazone ligands in DMSO-d6. 
Compound Ar C(R1)=N Aromatic C C(R1)=N C=S -(CH3)2 CH3 
12 2-pyrrole CH3 111.4-125.4 135.5 182.5 40.2 17.8 
16 2-furan CH3 111.8-121.3 144.0 146.0 43.1 17.1 
17 3-pyridine H 123.7-149.0 151.0 181.6 43.8 — 
18 3-pyridine CH3 123.3-150.1 152.2 183.1 44.1 12.5 
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The methyl carbons bonded to the terminal amine are found to be more upfield at 
40.2-44.1 ppm for all ligands.  However, the methyl carbons bonded to the imine 
moiety are the most upfield of all the carbons, with a peak at 12.5-17.8 ppm for all 3 
of the ligands where R1 = CH3. 
 
2.2.3. Infrared (IR) spectra of monothiosemicarbazones 
 
The IR spectra of the ligands are in accordance to the literature data for similar types 
of compounds.14 The characteristic medium-strong intense absorption bands in the 
range of 1583-1638 cm-1 for the thiosemicarbazone ligands are attributed to the 
imine functionality.  This is also confirmation of the ligands forming via a Schiff base 
condensation mechanism.  It is noted that the thiosemicarbazone ligands where R1 = 
CH3 (6-10, 12, 16, 18 and 21) have frequencies attributed to imine functionalities 
occurring slightly higher (1588-1638 cm-1) compared to their respective 
thiosemicarbazone ligands (1-5, 11, 13-15, 17 and 20) where R1 = H (1583-1628 cm-
1). This could possibly be due to the inductive effect (electron-donating) of the methyl 
group bonded to the imine. The N,N-dimethylthiosemicarbazone ligands (except for 
10, the 2-acetylpyridine derivative) are also found to occur at a higher frequency 
when compared to their non-substituted terminal amine thiosemicarbazone ligand 
derivatives.  The reason for this might be due to the electron donating property of the 
methyl groups on the N,N-dimethylthiosemicarbazones, which increases the electron 
density on the ligands and thus the frequency at which the functional groups vibrate 
will increase.  The IR spectra for the 4-phenylthiosemicarbazone derivatives also 
showed a peak at 1597 (medium intensity) and 1588 cm-1 (weak intensity) for the 2-
formylpyridine and 2-acetylpyridine derivatives, respectively.  The (NH) frequencies 
of the thiosemicarbazone ligands occur above 3000 cm-1. 
 
2.2.4. Melting points, elemental analyses and mass spectrometry of 
monothiosemicarbazones 
 
The melting point ranges (between 114°C and 213°C) of the 
monothiosemicarbazone ligands are found to be relatively high, with the exception of 
the 2-formylpyrrole-4,4-dimethylthiosemicarbazone which has a relatively low melting 
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point of 76-79°C. The melting points of the different known monothiosemicarbazone 
ligands are in close agreement with the literature melting points11,12,14-19 for the 
respective thiosemicarbazones.  The 2- and 3-formylpyridine thiosemicarbazone 
ligands have high melting points over 200°C, whereas the other thiosemicarbazone 
ligands have melting points just above 150°C.  This excludes 7 and 8, which have 
their melting points at 74-77°C and 114-115°C respectively.  It was noted that the 
N,N-dimethylthiosemicarbazones have lower melting points than their respective 
thiosemicarbazones with non-substituted terminal amines, with the exception of the 
2-acetylfuran derivative.  The 4-phenylthiosemicarbazone derivatives (20 and 21) are 
also found to have relatively high melting points (204-206°C and 173-177°C, 
respectively) when compared to the other 2-pyridine derivatives (with the exception 
of 5). 
 
The purity of the thiosemicarbazone ligands was confirmed by elemental analysis, 
which found the percentage composition of the elements to be in close agreement 
with the calculated values for their respective thiosemicarbazone ligands. Mass 
spectrometry (EI+) was also used for all new ligands (12, 16-18) where the four 
ligands show a peak accounting for the protonated molecular ion, i.e. [M + H]+.  
 
2.3. Dithiosemicarbazone ligands 
 
2.3.1. Synthesis of ethane-1,2-dithiosemicarbazide, 22. 
 
Dithiosemicarbazones have previously been reported in literature and have shown 
biological (i.e. antifungal and anticancer) activity.10,20,21 Literature has also shown 
that in some cases a multimeric system displays more biological activity than its 
monomeric counterpart22-25, thus dithiosemicarbazones were also ligands of interest 
to this study.  The method described by M. Christlieb et al.26 was used to prepare 
ethane-1,2-dithiosemicarbazide, 22, from ethane-1,2-diamine via the di-acid 
(Scheme 2.2).  The product, 22, was isolated as a white solid in a low yield of 40%. 
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Scheme 2.2: Outline to the synthesis of ethane-1,2-dithiosemicarbazide, 22. 
 
2.3.2. 1H-NMR spectrum of 22 
 
The 1H-NMR spectrum shows the same peaks (with similar shifts) as was reported 
by M. Christlieb et al.26 The ethane bridge protons appear as a singlet at 3.61 ppm.  
The singlet is due to the symmetrical nature of the compound.  The terminal 
(primary) amine proton peaks are slightly further downfield at 4.39 ppm as singlets, 
whereas the hydrazinic protons and the secondary amine protons (next to the ethane 
bridge) appear, as singlets, further downfield at 7.91 and 8.52 ppm, respectively. 
 
2.3.3. Melting point of 22 
 
The melting point of 22 is 213-214°C, which is in agreement with the literature 
melting point range of 212-214°C reported by T. Yabuuchi et al.27 
 
2.3.4. Synthesis of dithiosemicarbazones (23 and 24) 
 
Both ethylenedithiosemicarbazones, 23 (the newly synthesized 2-formylpyridine 
derivative) and 24, were prepared using the procedure described by Stringer et al.10 
and these reactions, as represented by equation (2.2), also proceeded via Schiff-
base condensation.  Acetic acid was used in the synthesis (as described by Al-
Hazmi et al.28) of the ligands where a methyl group (i.e. R = CH3) was bonded to the 
imine.  This is due to the fact that the ketones are less reactive than their respective 
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aldehydes. The 2-formylpyridine ethane-1,2-dithiosemicarbazone was also prepared 
in an ethanolic reaction mixture, which required a longer reaction time (24 hours).  
The dithiosemicarbazones were isolated as light-yellow solids in moderate to good 
yields (43% - 89%). 
 
H2N
H
N
S
H
N
N
H
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N
H
NH2
O
R
N
H
N
S
H
N
N
H
S
N
H
N
R
R
22: R = H
N
N
H2O
N
23: R = CH3
 
 
 
2.3.5. 1H-NMR spectra of dithiosemicarbazones (23 and 24) 
 
The 1H-NMR spectra of the dithiosemicarbazone ligands show a peak between 8.79-
8.80 ppm accounting for the protons on the secondary amines occurring next to the 
ethylene bridge (Fig. 2.6). The hydrazinic protons occur at 11.79 ppm for the 2-
formylpyridinedithiosemicarbazone ligand, whereas the 2-
acetylpyridinedithiosemicarbazone ligand’s hydrazinic protons occur more upfield at 
10.46 ppm. This is due to the inductive effect of the methyl group that shields the 
hydrazinic protons when compared to the formyl ligand. The protons attached to the 
imine bonds of 23 appear at 8.11 ppm, whereas the protons of the methyl groups 
attached to the imine bonds of 24 occur more upfield at 2.42 ppm.  The 2-pyridine 
ligands’ aromatic protons occur between 7-9 ppm. The 1H-NMR spectra of both 
dithiosemicarbazone ligands show the ethylene bridge protons occurring between 
3.88-3.93 ppm as singlets, due to the symmetrical nature of the ligands. 
 
3: R = H 
24: R = CH3 
…Eq. (2.2) 
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Fig. 2.6: 1H-NMR (in DMSO-d6) spectrum of 2-formylpyridinedithiosemicarbazone, 23 (representative 
spectrum). 
 
The pyridyl protons of the dithiosemicarbazones have similar chemical shifts 
between 7.38-8.60 ppm for both ligands (23 and 24), which compares favourably 
with the mononuclear 4,4-dimethylthiosemicarbazone derivatives 10 and 11 (Table 
2.6). The pyridyl protons of the mononuclear derivatives (10 and 11) have peaks 
appearing between 7.37-8.73 ppm.  The proton on the imine bond of 23, however, 
has its proton peak appearing at 8.12 ppm, further downfield compared to the 
mononuclear formyl derivative (7.50 ppm).  This was opposite to what was observed 
for the hydrazinic protons of the ligands where R = H. The mononuclear ligand has 
its hydrazinic proton further downfield compared to the dithiosemicarbazone 
derivative.  The same is observed with the derivatives where R = CH3 (i.e. the mono 
ligand has its hydrazinic proton more deshielded compared to the 
dithiosemicarbazone derivative).  The protons on the methyl bonded to the imine for 
both derivatives where R = CH3 has similar shifts around 2.4 ppm. 
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Table 2.6: Summary of 1H-NMR shifts (ppm) of 2-pyridine-dithiosemicarbazones (23 and 24) 
vs. 2-pyridine-4,4-dimethylthiosemicarbazones (10 and 11), i.e. mono- vs. binuclear ligands. 
Ligand pyr-H CH=N C(CH3)=N N
1
H N
2
H (CH2)2 
23: 
R=H 
7.38-8.56 8.12 — 11.80 8.80 3.88 
24:  
R=CH3 
7.39-8.60 — 2.42 10.43 8.80 3.93 
11: 
R=H 
7.37-8.63 7.50 — 15.10 — — 
10:  
R=CH3 
7.25-8.73 — 2.41/2.55 
/2.65 
8.46/14.82 
/15.51 
— — 
 
 
2.3.6. Infrared (IR) spectra and melting points of dithiosemicarbazones (23 and 
24) 
 
The characteristic medium-intense absorption band occurring between 1582-1587 
cm-1 for the dithiosemicarbazone ligands is attributed to the imine functionality.  This 
is also confirmation of the Schiff-base condensation reaction having taken place in 
the synthesis of the respective dithiosemicarbazone ligand.  The (imine) 
frequencies of the dithiosemicarbazones are found in similar regions to their 
mononuclear pyridyl counterparts (1582-1600 cm-1).  The (NH) frequencies of the 
dithiosemicarbazone ligands occur above 2900 cm-1. 
 
The melting point of the dithiosemicarbazone ligands are found to be relatively high 
when compared to their respective monothiosemicarbazone derivatives.  The 
dithiosemicarbazone ligand where R = H (227-229°C) has a higher melting point 
range than its dithiosemicarbazone ligand counterpart where R = CH3 (196-199°C).  
Ligand 24 is found to have a lower melting point when compared to the literature 
value of 214-216°C reported by Scovill.29 
 
The purity of the dithiosemicarbazone ligands was confirmed by elemental analysis, 
which found the percentage composition of the elements to be in close agreement 
with the calculated values for their respective dithiosemicarbazone ligands. 
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2.4. Conclusion/Summary 
 
A series of aromatic thiosemicarbazone ligands were synthesized. This series 
included four newly synthesized monomeric ligands and one newly synthesized 
dimeric ligand.  The ligands were characterized using 1H-NMR, 13C{1H}-NMR and IR 
spectroscopy, elemental analysis and mass spectrometry. Such characterizations 
confirmed the integrity of the ligands and showed that all of the compounds were 
sufficiently pure to be used in the synthesis of the respective 67Ga complexes.  
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Chapter 3: 
 
Synthesis and characterization of cold (non-
radioactive) and radiolabelled gallium(III) 
thiosemicarbazones. Biological evaluation of 
radiolabelled gallium(III) thiosemicarbazones. 
 
3.1. Introduction 
 
Gallium is a grayish semi-metallic element with an atomic number of 31, atomic 
weight of 69.72 amu and a melting point of 29.78°C.1,2 In most of its compounds 
gallium has an oxidation state of +3.2 The chemical behavior of gallium is closely 
associated to that of Fe3+, in terms of its electric charge, ion diameter, coordination 
number and its electron configuration.2 It has an electron configuration of 
[Ar]3d104s24p1, with the loss of two 4s electrons and one 4p electron yielding the 
stable trivalent cation Ga3+. The trivalent form of gallium is reported to be redox-
inactive, because gallium(II) would exhibit an energetically unfavourable [Ar]3d104s1 
electron configuration and because the process Ga3+  Ga4+ + e- would require 
considerable energy (6200 kJ.mol-1).1 Gallium is of particular interest as the metal is 
diamagnetic and does not suffer from the excited state relaxation through internal 
conversion.3   
 
Gallium(III) complexes have shown two biomedical properties worth exploiting for the 
development of antitumour gallium(III) compounds. Firstly, the anti-tumour activity of 
gallium(III) nitrate has been evaluated in phase I and phase II clinical trials4,5 after 
gallium nitrate had shown high antitumour activity in experimental animal tumours.6  
Secondly, 67Ga, a low energy gamma emitting radionuclide with a half-life of 78 
hours, is a very useful tumour diagnostic agent and has been used extensively 
(mostly as 67Ga-citrate) in the detection of a number of human malignancies.7,8   
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The careful choice of radionuclide allows gallium to be used as a PET (Photon 
Emitting Tomography) or SPECT (Single photon Emitting Computerised 
Tomography) imaging agent, depending on the radioisotope used.3 
 
In the earliest studies of gallium, it was found that the radioactive isotope 72Ga, a β-
emitter with a half-life of 14 hours that yields 72Ge,  could accumulate in animal 
tissues and some bone cancers.1,9,10 However, until recently, 67Ga bidimensional 
scintigraphy was the most widely used diagnostic modality for imaging patients with 
lymphoma.1,11 The interesting physical properties and availability of 67Ga has made it 
an interesting nuclide for radiopharmaceutical research.12,13 The interesting trend in 
the production and use of PET radionuclides in nuclear medicine has presented new 
opportunities for focused research on the production of new gallium-
radiopharmaceuticals for feasibility studies for future PET gallium homologs.12 
 
Gallium(III) thiosemicarbazones have shown promising anti-proliferative activity in 
vitro and in vivo.14  Due to the importance of thiosemicarbazones in antineoplastic 
activity and the necessity of gallium complexation to enhance their activity,12,15 the 
idea of developing possible tumour imaging agents incorporating 67Ga into suitable 
chelates, such as thiosemicarbazones, was investigated. 
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3.2. Synthesis of cold (non-radioactive) gallium(III) 
thiosemicarbazone complexes 
 
A ‘cold’ complex can be defined as a non-radioactive complex.  The main function of 
the cold complexes (in this study) was to confirm the structures of the radiolabelled 
complexes by comparing their respective HPLC profiles. The reactions (equation 
(3.1)) were performed under inert atmosphere. The gallium(III) thiosemicarbazone 
complexes (25-27) were synthesized by dissolving the respective ligand (6, 10 and 
11) in dry ethanol and adding dropwise a solution of GaCl3 (approximately 5 
equivalents) in dry ethanol.  Care was taken in the handling of the air- and moisture-
sensitive GaCl3 which was weighed out in a glove-box.  For the synthesis of 26 the 
reaction mixture was stirred at room temperature for 2 hours, whereas for the 
synthesis of 25 and 27 the reaction mixture was refluxed for 2 hours.  The synthesis 
for all complexes produced bright-yellow solids in moderate to good yields (54% - 
75%).  The gallium(III) complexes were also found to be soluble in ethanol, 
methanol, acetone and DMSO. 
 
N
R1
N
H
N
S
R2
GaCl3/ dry EtOH
N
R1
N
N
S
R2
Ga
Cl Cl
10: R1 = CH3, R2 = N(CH3)2
11: R1 = H, R2 = N(CH3)2
6: R1 = CH3, R2 = NH2
25: R1 = CH3, R2 = NH2
26: R1 = CH3, R2 = N(CH3)2
27: R1 = H, R2 = N(CH3)2  
 
…Eq. (3.1.) 
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In the synthesis of the complexes, the gallium serves as the Lewis acid (soft) 
whereby it accepts electrons from the tridentate (thiolate sulfur, imine nitrogen and 
pyridyl nitrogen) thiosemicarbazone ligand.  It should be noted that in order to obtain 
a 1:1 ligand to metal ratio complex, GaCl3 was added in excess (more than 5 
equivalents) during the synthesis.  This was employed to prevent the possibility of 
different ratios of gallium(III) to thiosemicarbazone complexes forming.7  Of the 
complexes formed, 25 and 26 had previously been reported by Kratz et al.7, whereas 
27 was newly synthesized.  The complexes were characterized using 1H-NMR and 
IR spectroscopy, as well as by melting point determination and elemental analysis. 
 
3.2.1. 1H-NMR spectra of cold complexes (25-27) 
 
The 1H-NMR spectrum of 26 shows the pyridyl proton peaks appearing between 
7.57-8.25 ppm. The protons on the methyl group attached to the imine bond are 
found to appear at 2.77 ppm, whereas the protons on the methyl groups attached to 
the tertiary amine appear slightly more downfield at 3.31 ppm.  
 
 
Fig. 3.1: 1H-NMR spectra of 2-formylpyridine-4,4-dimethylthiosemicarbazone, 11, (ligand) and 
gallium(III)-2-formylpyridine-4,4-dimethylthiosemicarbazone, 27 (complex). 
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The 1H-NMR spectrum of 27 (Fig. 3.1) shows the pyridyl proton peaks appearing 
between 7.57-8.80 ppm, slightly shifted downfield when compared to 26 due to the 
shielding effect of the electron-donating methyl group attached to the imine of 26.  
The spectrum of 25, however, shows the pyridyl protons slightly further downfield 
when compared to 26 and 27.  The reason for this might be due to the electron-
donating methyl groups on the terminal amine of 26 and 27 that provide some 
shielding when compared to 25, which has a free terminal amine (i.e. no electron 
donating group).  The spectrum of 25 also shows a downfield shift of the pyridyl 
protons when compared to ligand 6 (Table 3.1).  A downfield shift is also seen in the 
spectrum of 25 for the protons on the methyl group attached to the imine bond when 
compared to the respective ligand.  The protons on the methyl groups attached to 
the terminal/tertiary amine of 27 appear at 3.27 ppm, similar to 26 (3.31 ppm). The 
peak for the proton bonded to the imine moiety of 27 appears at 8.47 ppm.  There 
are downfield shifts of the pyridyl and imine protons of 27 when compared to its 
respective ligand (Fig. 3.1).  Most notably, there is no peak seen for the hydrazinic 
proton which suggests that the complexation occurs via the thiolate form of the 
ligand.  The complexation via the thiolate form of the ligand is also reported by Kratz 
et al.7 
 
Table 3.1: Summary of the 1H-NMR shifts (ppm) of the complexes (25-27) vs. their respective ligands 
(6, 10 and 11). 
Compound pyr-H CH=N C(CH3)=N NH 
25 7.90-9.02 — 2.72 — 
6 7.40-8.60 — 2.41 10.29 
26 7.57-8.25 — 2.77 — 
10 7.25-8.73 — 2.41/2.55/2.65 8.46/14.82/15.51 
27 7.76-8.80 8.47 — — 
11 7.37-8.63 7.50 — 15.10 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 3 Results and Discussion: Thiosemicarbazone Complexes 
 
61 
3.2.2. Infrared (IR) spectroscopy of cold complexes (25-27) 
 
The characteristic strong and medium intense absorption bands occurring at 1603 
(s) and 1558 cm-1 (m) for 25, 1601 (s) and 1553 cm-1 (m) for 26 and 1606 (s) and 
1566 cm-1 (m) for 27 are attributed to the imine functionalities.  The second imine 
band is also confirmation that the sulphur bonds to the metal in the thiolate form. The 
IR spectra show a shift of the imine band from 1599, 1582 and 1592 cm-1 (ligands) to 
1603, 1601 and 1606 cm-1 for 25, 26 and 27, respectively (Table 3.2).   
 
Table 3.2: Summary of the imine (C=N) band frequencies in the infrared spectra (using KBr 
pellets) of the complexes (25, 26 and 27) vs. their respective ligands. 
 (C=N), cm
-1
 
Compound Ligand Complex 
6/25 1599 1603, 1558 
10/26 1582 1601, 1553 
11/27 1592 1606, 1566 
 
 
3.2.3. Melting point determination, elemental analysis and mass spectrometry 
of cold complexes (25-27) 
 
The melting point of 26 was determined to be 251-254°C. The melting point of 27 is 
relatively low between 116-120°C when compared to 26.  Elemental analysis of the 
complexes (25-27) is in close agreement with the calculated values for the 1:1 ligand 
to metal ratio complexes, supporting the integrity of the cold complexes. Mass 
spectrometry (EI+) was also used to further characterize the complexes (25-27) 
where the complexes show a peak accounting for the molecular ion, i.e. [M]+. 
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3.3. Synthesis and characterisation of 67Ga complexes 
 
3.3.1. Synthesis of radiolabelled complexes (28-34) 
 
The synthesis of the 67Ga complexes (28-34) was performed by adding an ethanolic 
solution of the relative ligand to 67GaCl3 pre-dried from an aqueous or acetonic 
solution. The reaction mixture was heated at ~80°C for 20-60 minutes to give the 
radiolabelled complex (28-34) in a high (quantitative) radiochemical yield.  The 
radiochemical yield can be expressed as a percentage of the activity originally 
present. The synthesis of the radiolabelled gallium(III) thiosemicarbazones differed 
slightly from that of the cold (non-radioactive) gallium(III) thiosemicarbazones with 
respect to the reaction conditions (i.e. time and temperature). 
 
                                          
N
N
N
S
NH2
Ga
Cl Cl
67
       
                                  
N
N
N
S
N
R
Ga
Cl Cl
67
 
                              
N
N
N
S
H
N
Ga
Cl Cl
67
R
  
            
N
N
N
S
H
N
Ga
Cl Cl
67
N
H
S
N
N
NGa
ClCl
67
R
R
 
 
Fig. 3.2: Proposed structures of 67Ga thiosemicarbazone complexes (28-34). 
 
29: R = CH3 
30: R = H 
31: R = H 
32: R = CH3 
33: R = H 
34: R = CH3 
28 
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3.3.2. High Performance Liquid Chromatography (HPLC) analysis of 
radiolabelled complexes (28-34) 
 
The radiolabelling of ligands with a gallium cation affects their chromatographic 
properties and the final complexes (Fig. 3.2) are found to be less polar than their 
respective ligands.16 HPLC radiochromatograms are generated by detecting the 
separated radioactive components in the column effluent with a radioactivity 
detector. Radiochromatograms of the successfully radiolabelled complexes show the 
presence of a new peak, with free 67GaCl3 eluting early at 2.9-3.0 minutes (Fig. 
3.3(i)).  The successfully radiolabelled complexes (28-34) are found to exhibit high 
radiochemical yields of at least 87%.  All successful radiolabelling experiments were 
performed in duplicate. 
 
 Fig. 3.3: HPLC chromatograms of (i) free 67GaCl3 (2.9-3.0 min.) and (ii) [67Ga]-2-acetylpyridine-4,4-
dimethylthiosemicarbazone (12.6 min.). 
 
The chromatograms of 28, 29 and 30 show the presence of a new peak at 5.5, 12.6 
and 11.8 minutes, respectively, as well as labelling efficiencies (Table 3.3, Fig. 3.4) 
of 87% (for 28) and more than 99% (for 29 and 30).  The chromatograms of 31 (13.0 
minutes) and 32 (13.7 minutes) also show high yields of 90% and more than 99%, 
(i) (ii) 
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respectively.  The chromatograms of 33 and 34 each show a broad radiolabelled 
complex peak with a smaller peak on the shoulder (i.e. at the start of the broad 
peak). Compound 34 shows more than 99% labelling efficiency when accounting for 
the total sum of the major and minor peaks, while 33 shows approximately 95% 
labelling efficiency when accounting for both peaks.  The major peaks appear at 11.5 
(85%) and 12.5 (91%) minutes for 33 and 34, respectively.  The minor peaks, 
appearing at 10.7 (11% ) and 11.3 minutes (~ 9%) for 33 and 34, respectively, could 
possibly arise from the 67Ga cation binding only to 1 site in the ligand or as a result of 
possible isomerization of the ligand in the ethanolic solution before complexation. 
The latter is more likely as the HPLC chromatogram of the ligands show 2 significant 
peaks for both ligands (i.e. 23 and 24). The chemical/molecular identities of 28-30 
were ascertained by comparison of their HPLC profiles with those of the 
corresponding cold complexes (25-27). The structures of 31-34 were obtained by the 
apparent binding nature of gallium-67 to a 2-pyridinethiosemicarbazone ligand (i.e. in 
a N,N,S-tridentate manner).  
 
Table 3.3: Summary of the successfully radiolabelled complexes, their retention times using 
HPLC, their radiolabelling efficiency and the comparison with the cold complexes. 
Radio-
labelled 
complex 
Ar R
2
 R
1
 Labelling(%) 
Radio-
labelled 
complex, 
tr(min.) 
Cold 
complex, 
tr(min.) 
28 2-pyridine CH3 NH2 87 5.5 5.5 
29 2-pyridine CH3 N(CH3)2 >99 12.6 12.6 
30 2-pyridine H N(CH3)2 >99 11.8 11.5 
31 2-pyridine H NH(C6H5) 90 13.0 —b 
32 2-pyridine CH3 NH(C6H5) >99 13.7 —b 
33 2-pyridine H NH(CH2)2-TSC 95 10.7-11.5a —b 
34 2-pyridine CH3 NH(CH2)2-TSC >99 11.3-12.5a —b 
aA broad peak is observed for the [67Ga]-dithiosemicarbazone complexes, with a relatively small peak 
at the shoulder. bCold complex was not synthesized. 
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Fig. 3.4: Structure of thiosemicarbazone ligands used in the radiolabelling studies. 
 
Table 3.4: Summary of the ligands that were unsuccessfully radiolabelled. 
Ligand Ar R
2
 R
1
 Ligand Ar R
2
 R
1
 
1 Benzene H NH2 12 2-pyrrole CH3 N(CH3)2 
2 2-furan H NH2 13 2-pyrrole H N(CH3)2 
3 Benzene H N(CH3)2 14 2-pyrrole H NH2 
4 3-pyridine H NH2 15 2-furan H N(CH3)2 
5 2-pyridine H NH2 16 2-furan CH3 N(CH3)2 
7 2-furan CH3 NH2 17 3-pyridine H N(CH3)2 
8 Benzene CH3 NH2 18 3-pyridine CH3 N(CH3)2 
9 2-pyrrole CH3 NH2     
 
 
There are some thiosemicarbazone ligands (Table 3.4) that cannot be labelled with 
67Ga. When comparing their structures with those of the ligands that were 
successfully labelled, there appears to be a few structural conditions for successful 
labelling. It was found that the presence of 2-pyridine (or perhaps any 6 membered 
heteroaromatic group, with the heteroatom at the 2-position) in conjunction with an 
electron donating group (methyl) on the imine carbon atom and/or the presence of 
lipophilic non-polar groups (such as methyls or phenyls) on the terminal amine 
provide the best structural features for thiosemicarbazone ligands to ensure 
successful labelling with 67Ga. There are two possible reasons that the ligands in 
Table 3.4 could not be labelled with 67Ga: (i) the orientation of the lone pair(s) on the 
heteroatom are not suitable for complexation as they would face away from the 
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gallium already coordinated to the thiolate sulphur (the negatively charged sulphur 
would act as a more powerful nucleophile relative to heteroatoms with a lone pair), 
and (ii) the proximity of the lone pair(s) relative to the already bound gallium.17  The 
solubility of the ligand in ethanol (as influenced by, amongst others, the lipophilic 
groups on the terminal amine) could also be an important characteristic. However, if 
the ligand is soluble in ethanol it does not necessarily mean that it would be 
successfully labelled with 67Ga. 
 
3.3.3. Comparison between mono- and bi-nuclear ligands in labelling with 67Ga 
 
When looking comparatively at the mono- and bi-nuclear ligands with regards to their 
labelling efficiencies with 67Ga, it can be seen that there are no significant differences 
in the incorporation of the 67Ga into the ligands. The amount of 67Ga used in the 
reactions ranged between 1.26 and 1.46 mCi. The mono-nuclear ligands (29 and 30) 
show >99% labelling efficiencies, whereas the bi-nuclear ligands (33 and 34) show 
95% and >99% incorporation of 67Ga, respectively. This is, however, not a 
conclusive study of the effects of using a bi-nuclear versus a mono-nuclear ligand in 
labelling with 67Ga.  More conclusive evidence might be obtained by using a range of 
smaller amounts of the ligands. 
 
3.3.4. Effect of 67GaCl3 quality 
 
When a 67GaCl3 batch was between 2-3 days old, the radiochemical yield is found to 
remain approximately the same. This is contradictory to what has been reported by 
Haghighi Moghadam et al.16, who claim that when a 67GaCl3 batch was older than 2 
days, the radiochemical yield drastically drops. This could be explained by the 
formation of non-radioactive zinc atoms during the decay process, resulting in the 
latter competing with radiogallium for complexation with the ligands. Zn-
thiosemicarbazone complexes are reported to be very stable18. It is obvious that, in 
the current study, the number of atoms of the decay product Zn was not sufficiently 
high enough to compete with the radioactive 67Ga atoms for complexation. It is, 
however, noted that, as a result of the decay process, a 67GaCl3 batch loses some of 
its activity after 2 days.  This was compensated for by using a bit more of the 67GaCl3 
solution in order to maintain a similar starting activity for each reaction. 
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3.4. Stability Studies of 67Ga complexes (28-34) 
 
The radiochemical stabilities (i.e. ability to retain the 67Ga radionuclide under 
specified conditions) of the successfully radiolabelled complexes (28-34) were also 
tested in saline solution (0.9% NaCl in water) and bovine serum. The stability of the 
radiolabelled complexes (Fig. 3.5) was tested by incubating the respective 
radiolabelled complex in 50 µL of saline/serum solution at 37°C for 30, 60 and 120 
minutes, respectively. Each test (saline/serum) for a specific time period (30, 60 and 
120 minutes) was performed individually (i.e. no removal of aliquots). After 
incubation, the proteins (from the serum test) were precipitated with 50 µL 
acetonitrile, as is described by Kumar et al.19 The samples were centrifuged for 
approximately 1 minute and the cleared lysate was analyzed by HPLC to assess the 
integrity of the radiolabelled complex.  
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Fig. 3.5: Radiolabelled complexes (28-34) that were tested for their stability. 
29: R = CH3 
30: R = H 
31: R = H 
32: R = CH3 
33: R = H 
34: R = CH3 
28 
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It was found that the radiolabelled complexes are all stable in saline solution. This 
implies that they are all stable against radiolysis. However, only 29 and 34 are 
relatively stable in the bovine serum (Fig. 3.6). The stability test of 29 in bovine 
serum shows that there is little decrease in stability of 29 after 2 hours of incubation 
at 37°C. The graph (Fig. 3.6A) shows 95%, 97% and 90% radiolabelled complex 
(29) present after 30, 60 and 120 minutes, respectively. The serum (or protein within 
the serum), however, has a more profound effect on 34. The graph shows 91%, 67% 
and 66% radiolabelled complex (34) present after 30, 60 and 120 minutes, 
respectively. The graph (Fig. 3.6B) also shows that there is a levelling off of the 
percentage of 34 remaining after 1 hour. Stability tests with all other successfully 
radiolabelled complexes show less than 3% of the radiolabelled complex remaining 
after 30 minutes. This implies that only 29 and 34 are suitable candidates for further 
biological studies. The serum instability of the other radiolabelled complexes could 
be ascribed to possible interaction with the protein molecules in the serum, which 
results in the expulsion of the radiometal from the ligand. This interaction comprises 
an exchange of the gallium between the radiolabelled complex and the 
apotransferrin in the serum.20 This means that in vivo testing of these radiolabelled 
complexes would most likely show that the complexes would not survive the body’s 
physiological conditions. 
 
 
       
 
Fig. 3.6: Stability study of (A) 29 and (B) 34 in bovine serum (at 37°C). 
 
 
 
A B Stability of 29 in bovine serum Stability of 34 in bovine serum 
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3.5. Effect of water on radiolabelling efficiency 
 
Two of the successfully radiolabelled complexes (28 and 29) representing the 
relatively least and most efficiently radiolabelled complexes, respectively, were 
selected for the study of the effect of water on the radiolabelling efficiency of 
gallium(III) thiosemicarbazones. This study was performed to test a claim made by 
Jalilian et al.12 who stated that the labelling of a thiosemicarbazone with gallium-67 is 
not satisfactory when water is present in the reaction solvent. The radiolabelling 
reactions were performed with varying percentages (0% - 40%) of water present in 
the reaction mixtures. Both results show that water has no significant effect on the 
radiolabelling efficiency (Fig. 3.7). These results, thus, contradict the statement 
made by Jalilian et al.12 
 
     
 
Fig. 3.7: Effect of water on radiolabelling efficiency of (A) 28 and (B) 29. 
 
3.6. Biological evaluation of the 67Ga complexes: in vitro cellular 
uptake studies 
 
The in vitro cellular uptake experiments were performed to test the ability of the 
radiolabelled complexes (29 and 34) to bind to various cell lines, such as a rat 
ovarian cancer cell line (DMBA OC1R), human breast cancer cell line (MCF 7) and 
non-cancerous brain endothelial cell line (bEND5) as the control. The cells, grown in 
culture flasks, were trypsinized, released and re-suspended in cell growth medium. 
The cells were allowed to attach and grow in the medium for four hours. Cells were 
seeded in quantities of 50 000, 100 000, 150 000, 200 000 and 250 000 cells per 
A B Effect of water on radiolabelling 
efficiency of 28 
Effect of water on radiolabelling 
efficiency of 29 
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well in 24-well plates. It was noted that the non-cancerous brain endothelial cell line 
had the fastest cell kinetics compared to the cancer cell lines, which is opposite to 
what happens in vivo (i.e. the cancer cells grow faster). The cell kinetics is 
determined by how fast the cells undergo cell division (Fig. 3.8). 
 
 
 
 
 
 
 
 
 
Fig. 3.8: A cycle summizing the cell division of the cells.  
 
The radiolabelled compound was added to each well in a final concentration of 1.36 
µCi/well to three sets of 24 well plates, containing the bEND5, DMBA OC1R and 
MCF 7 cells, respectively. The cultures were incubated for 2 hours (at 37°C) to allow 
uptake of the radiolabelled compounds. After incubation the cultures were 
terminated, and the medium and extracellular activity were removed by repeatedly 
washing the cells with phosphate buffered saline solution. The cell monolayer was 
lysed using 1M NaOH and transferred to test tubes to quantify radioactivity. 
Radioactivity bound to the cells was quantified in a gamma () counter and is 
reported (in Table 3.5) as a factor of the counts from the  counter measured in one 
minute to the total cell count multiplied by 100 (i.e. [counts from the  counter in one 
minute / total cell count] x 100). 
 
The results (Fig. 3.9) show that there are clearly more uptake of the radiolabelled 
complexes (29 and 34) into the non-cancerous brain endothelial cells compared to 
the cancer cell lines. This correlated to the cell kinetics of the cell lines, and since 
cancer cells grow much faster in vivo, SPECT imaging studies of carcinoma-bearing 
mice would give a better understanding of the cellular uptake of these radiolabelled 
complexes. The results do show that 29 has better cellular uptake into both cancer 
Mitosis 
Rest 
Phase 
Rest 
Phase 
DNA 
Synthesis 
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cells compared to 34. This could be attributed to the increased solubility of 29 
compared to 34. 
 
  
  
Fig. 3.9: The results of in vitro cellular uptake studies of (A) 29 and (B) 34. 
 
Table 3.5: The average comparative cellular uptake ([counts from the  counter in one 
minute / total cell count] x 100) of 29 and 34 into the various cell lines. 
Compound bEND5 MCF 7 DMBA OC1R 
29 2.15 1.30 1.16 
34 1.79 N/Aa 0.91 
aThe background  count was found to be higher than the total  count  
after cellular uptake studies. 
 
3.7. Conclusions/Summary 
 
The total labelling of the thiosemicarbazone ligands with 67Ga took 20-60 minutes, 
with a radiochemical purity of at least 87% achieved. All the radiolabelled complexes 
(A) 
(B) 
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(28-34) are stable in an aqueous solution. However, only 29 and 34 relatively are 
stable in bovine serum, for 2 hours at 37°C. Studies show that the presence of water 
(up to 40%) in the reaction mixture has no significant effect on the radiolabelling 
efficiency. Cellular uptake studies (in vitro) of 29 and 34 show that there is more 
uptake into the non-cancerous brain endothelial cells compared to the cancerous 
cells. The results also show that 29 (mononuclear ligand) has better cellular uptake 
in the rat ovarian cancer and human breast cancer cells compared to 34 (binuclear 
ligand). In vivo studies would give a better indication as to the promise these 
compounds possess as imaging agents and it would also show how they compare 
against existing imaging agents.  
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Chapter 4: 
 
Preliminary investigation into the synthesis of 
radiolabelled palladium(II) poly(aryl)ether 
dendrimers. 
 
4.1. Introduction 
 
In recent years, medicinal chemists have begun to realize the key role that 
dendrimers may play in the future of medicine.1 Dendrimers consist of a core 
encased within concentric shells formed by covalently linked branches, as is 
described in chapter 1.5.1-3 It has been reported that the field of oncology will soon 
be revolutionized with the use of dendrimer-based nanodevices in novel strategies 
for diagnoses and therapy.1 Cancer diagnoses via magnetic resonance imaging 
(MRI) could also be improved by incorporation of dendrimers as advanced contrast 
agents.1 Dendrimers have also been reported to serve as a central platform for a 
new generation of nanodevices designed to be multifunctional diagnostic and 
therapeutic agents.1 The average size and structure of a dendrimer within a batch 
can be controlled by precisely eproducing the expansion of the branching network.1 
 
Dendrimers have two routes of being synthesized, which is described in chapter 1.5. 
Dendrimers used for in vitro and in vivo testing have been synthesized from a 
number of dendritic structures.1 Terminal branches of reactive dendrimers can be 
capped off to neutralize toxicity,4-6 increase biopermeability4 and to prevent non-
specific targeting during delivery.1,2 Furthermore, terminal groups can be modified to 
obtain both a charged and hydrophilic or hydrophobic function for the desired 
biological and drug delivery application.3,7 They are also ideal drug delivery systems 
due to their topology, functionality and dimensions; and their size is also very close 
to various important biological polymers and assembles.3,8  
 
There is a degree of control over the nature and functionality of both the internal 
building blocks9 and the chain ends10,11 in the convergent synthesis of the dendritic 
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structures.12 The possibility thus exists for the synthesis of unimolecular dendritic 
micelles capable of specific non-bonding interactions through specifically-made 
molecular inclusion sites.12 It has been shown that this can be achieved through the 
synthesis of poly(aryl)ether dendritic macromolecules via the convergent growth 
approach.12  
 
While dendrimers reported so far are organic in nature, there is a rising interest in 
metallodendrimers.13-17 These metallodendrimers are particularly interesting as the 
metals can be combined into different parts of the dendritic structure.13 It has been 
reported18 that an increased number of interstrand crosslinks is a key reason for the 
high activity of di-nuclear compounds against cisplatin-resistant cell lines.19 This has 
increased the efforts in developing molecules that will give rise to an increased 
number of interstrand adducts, and synthesizing multinuclear metallic compounds 
such as metallodendrimers is said to be a viable approach in developing new 
drugs.19 
 
Enhancement of magnetic resonance imaging (MRI) diagnostic sensitivity can be 
achieved through the utilization of dendrimer-based contrast agents.1 It has been 
reported that targeted delivery of contrast agents have the ability to improve the 
contrast between cancerous tissue and healthy tissue.1 Targeted methods have 
proven to promote nanodevice internalization specifically by cancer tissue.1 
 
Interesting biological results using metallodendrimers as potential anticancer agents 
from Smith and co-workers have also been published.20,21 Thus, a dendrimer 
labelled with a radioisotope should provide an interesting look into possible new 
radioimaging and radiotherapeutic drugs. As there are little to no reports of palladium 
radioisotopes being used for medicinal purposes, dendrimers radiolabelled with 
palladium-109 should prove to be an interesting venture into developing new 
radiopharmaceuticals. 
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4.2. Synthesis of dendritic core and wedges (G0 and G1) 
 
4.2.1. Synthesis of 2,3-bis(2-methyl-4-hydroxylphenylimino) butane, 35. 
 
O O
+ H2N OH2
MeOH
/Formic acid
HO N N OH
/24 hours (r.t.)
35  
 
The procedure for the synthesis (equation (4.1)) of this dendritic core, 35, was 
described by Blom et al.22 The product was isolated as a yellow/brown solid in a low 
yield (40%). The para-hydroxyl group allows attachments of various dendritic 
wedges containing an alkylbromide functionality at the focal point. Using the 
Williamson ether synthesis, a quantitative yield of dendritically functionalized α-
diimine ligands can be expected. Frechet and co-workers12 reported the quantitative 
build-up of poly(aryl)ether dendrimers when applying mild reaction conditions. 
 
4.2.2. 1H-NMR spectrum of 35. 
 
The 1H-NMR spectrum (Fig. 4.1) showed the same peaks (with similar shifts) as was 
reported by Blom et al.22 The spectrum shows a broad singlet peak at 7.99 ppm 
which accounts for the proton on the hydroxyl groups. The spectrum also displays 
two doublets and one singlet between 6.45-6.75 ppm accounting for the aromatic 
protons. The protons on the methyl groups attached to the imine bonds and aromatic 
groups appear further upfield at 2.09 ppm and 2.03 ppm, respectively. 
 
…Eq. (4.1) 
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Fig. 4.1: The 1H-NMR spectrum of the dendritic core, 35. 
 
 
4.2.3. Infrared spectrum and melting point of 35. 
 
The infrared spectrum shows the presence of a strong intensity absorption band at 
1629 cm-1 attributed to the imine functionality. This further confirms the formation of 
35 via the presence of imine bonds (i.e. Schiff-base condensation reaction).  The 
melting point of 35 occurs between 122-125°C.  This is similar to what was reported 
by Blom et al.22 
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4.2.4. Synthesis of Methyl p-bromomethylbenzoate (G0 wedge), 36. 
 
    
OHH3CO
O
BrH3CO
O
PBr3/dry toluene
36  
 
The procedure for the synthesis of 36 (equation (4.2)) was carried out in accordance 
with that described by Hawker et al.4, with the exception that dry toluene was used 
instead of dry benzene. A mixture of methyl p-hydroxymethylbenzoate and 
phosphorus tribromide was allowed to react for 2 hours at room temperature. After 
the necessary washings and extractions, the product was isolated as a white solid in 
a good yield (87%). 
 
4.2.5. 1H-NMR spectrum and melting point of 36. 
 
The 1H-NMR spectrum (Fig. 3.1) shows similar peaks as is reported by Hawker et 
al.4 The spectrum shows a singlet appearing upfield at 3.90 ppm accounting for the 
protons on the methyl group. The peak for the protons on the alkylbromide (-CH2-) 
appears as a singlet slightly more downfield at 4.48 ppm, whereas the peaks for the 
aromatic protons appear the most downfield at 7.44 ppm and 7.98 ppm as two 
doublets. The melting point range of 36 was recorded to be 51-53 °C, which is 
similar to the literature melting point range of 53-55 °C reported by Aizpurua et al.23 
 
Fig. 4.2: The 1H-NMR spectrum of the G0 wedge, 36. 
 
…Eq. (4.2) 
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4.2.6. Synthesis of dendritic benzyl alcohol (G1), 37. 
 
OH
O
O
H3CO
O
H3CO
O
OH
HO
HO
BrH3CO
O
+
K2CO3/ 18-c-6
/dry acetone/ reflux, 24 h
36
37  
 
The reaction for the synthesis of 37 was performed under an inert atmosphere. In the 
synthesis of 37 the reaction of two molar equivalents of methyl p-
bromomethylbenzoate (36) to one molar equivalent 3,5-dihydroxybenzyl alcohol 
(equation (4.3)) occurred r adily in the presence of potassium carbonate and 18-
crown-6 in acetone heated at reflux.  The potassium carbonate serves as a base that 
deprotonates the hydroxyl groups directly bonded to the benzene in 3,5-
dihydroxybenzyl alcohol.  The reaction gave the product, 37, as a white solid in a 
moderate yield (63%). 
 
4.2.7. 1H-NMR spectrum of dendritic benzyl alcohol (G1), 37. 
 
The 1H-NMR spectrum of 37 corresponded to the literature report by Hawker et al.12 
The proton from the hydroxyl group is found to be most upfield at 3.66 ppm. The 
protons from the methoxy group, as well as the alkyl protons are also found to be 
upfield between 3.92-5.10 ppm as singlets. The aromatic protons on the benzyl 
alcohol moiety appear at 6.51 ppm and 6.61 ppm as a doublet and a triplet, 
…Eq. (4.3) 
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respectively, due to long range coupling.  The aromatic protons on the benzoate 
moiety are found to be the most downfield at 7.47 ppm and 8.03 ppm as doublets. 
 
4.2.8. Infrared (IR) spectrum and melting point of dendritic benzyl alcohol (G1), 
37. 
 
The infrared spectrum of 37 shows similar bands to that reported by Hawker et al.12 
The spectrum shows the presence of a medium intensity absorption band at 1715 
cm-1 attributed to the C=O functionality. The melting point of 37 was duplicated and 
recorded to be 56-59 °C. 
 
4.2.9. Synthesis of dendritic benzyl bromide (G1 wedge), 38. 
 
OH
O
O
H3CO
O
H3CO
O
37
Br
O
O
H3CO
O
H3CO
O
38
PBr3/PPh3
   /acetone/24 hrs, rt.
 
 
The procedure for the synthesis of 38 (equation (4.4)) is a modification to the 
method described by Hawker et al.12 A mixture of dendritic benzyl alcohol (37), 
phosphorus tribromide and triphenylphosphine in acetone was stirred vigorously for 
24 hours. After the necessary washings and extractions, the product (38) was 
isolated as a white solid in a moderate yield (54%). 
…Eq. (4.4) 
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4.2.10. 1H-NMR spectrum of dendritic benzyl bromide (G1 wedge), 38. 
 
The 1H-NMR spectrum (Fig. 4.3) displays all the expected peaks and correlates to 
the literature spectrum reported by Hawker et al.12 When compared to the 1H-NMR 
spectrum of the dendritic benzyl alcohol, the absence of the hydroxyl peak in the 
spectrum of the product, 38, is the most notable feature. The spectrum shows a 
singlet peak upfield at 3.92 ppm accounting for the protons on the methyl groups and 
two singlet peaks at 4.24 ppm and 5.10 ppm accounting for the alkyl protons (i.e. –
CH2Br and –OCH2–). The aromatic proton peaks appear in the same region, with the 
same multiplicities, as is seen in the spectrum of 37 (i.e. between 6.51-8.03 ppm). 
 
 
Fig. 4.3: The 1H-NMR spectrum of the G1 brominated wedge, 38. 
 
4.2.11. Infrared (IR) spectrum, melting point, elemental analysis and mass 
spectrometry of dendritic benzyl bromide (G1 wedge), 38. 
 
The infrared spectrum of 38 also shows similar bands to that reported by Hawker et 
al.12 The spectrum shows the presence of a medium intensity absorption band at 
1720 cm-1 attributed to the C=O functionality. The melting point of 38 was recorded to 
be 137-140 °C, which is similar to the reported melting point of 139-140°C by 
Hawker et al.12 Elemental analysis of 38 shows all the values are in close agreement 
with the calculated values. Mass spectrometry (EI+) shows a 100% molecular ion 
peak accounting for the product molecule (i.e. m/z 499.7, [M]+). 
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4.3. Synthesis of dendritic ligands, 39 (G0) and 40 (G1) 
 
 
N N OHHO
35
dry THF/18-crown-6
/K2CO3/reflux, 48 hrs
G1 wedge (38)G0 wedge (36)
N N OO
OCH3
O
H3CO
O
NO
O
O
O
O
OCH3
OCH3
2
39 40  
 
The reactions (equation (4.5)) were performed under inert atmosphere. The 
dendritic ligands (39 and 40) were prepared using the standard Williamson ether 
synthesis, whereby 2,3-bis(2-methyl-4-hydroxylphenylimino)butane (35) was reacted 
with two molar equivalents of the dendritic benzyl bromides (36 or 38).  Hawker et 
al.12 previously reported the synthesis of poly(aryl)ether dendrimers and applying the 
same conditions the dendritic ligands (39 and 40) were synthesized in dry 
tetrahydrofuran heated under reflux, using potassium carbonate as a base and 18-
crown-6 as a phase transfer catalyst. The product (39 or 40) was separated from the 
inorganic salts using an aqueous work-up. The dendritic ligands were isolated as an 
orange-brown solid (39) and orange oil (40) in moderate to low yields of 57% and 
28%, respectively. 
 
 
 
 
…Eq. (4.5) 
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4.3.1. 1H-NMR spectra of dendritic ligands, 39 (G0) and 40 (G1). 
 
The 1H-NMR spectra of the ligands accounted for all expected proton peaks.  The 
methyl protons appear upfield at 2.03 ppm and 2.10 ppm (for both sets of methyl 
protons) for 39 (Fig. 4.4) and 40, respectively, whereas the methoxy proton peaks 
appear at 3.81 ppm and 3.92 ppm for 39 and 40, respectively.  The alkyl proton 
peaks appear slightly more downfield at 5.63 ppm for 39 and 4.98-5.11 ppm for 40. 
The methyl and alkyl proton peaks appear as singlets. The aromatic proton peaks of 
the benzyl groups adjacent to the imine bonds appear in the region between 6.58-
6.90 ppm (39) and 6.62-6.97 ppm (40), as a singlet and two doublets in each 
spectrum. The protons on the terminal benzene moieties display proton peaks in 
similar regions for 39 and 40 (i.e. 7.56-7.93 ppm and 7.56-8.05 ppm, respectively). 
The peaks occurring at 6.50 ppm and 6.58 ppm in the spectrum of 40 are due to the 
protons on the benzene adjacent to the three alkoxy groups. 
 
 
Fig. 4.4: The 1H-NMR spectrum of the G0 ligand, 39. 
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4.3.2. Infrared spectra, melting point, elemental analysis and mass 
spectrometry of dendritic ligands, 39 (G0) and 40 (G1). 
 
The characteristic medium intense absorption band occurring at 1638 cm-1 and 1636 
cm-1 in the IR spectra of 39 and 40, respectively, are attributed to the imine 
functionality. This band is at a slightly higher frequency when compared to the 
absorption band at 1629 cm-1 attributed to the imine functionality of the core, 35. This 
could possibly be due to the added wedge decreasing the electron withdrawing 
effect of the oxygen on the core component of the ligand. There are also bands 
above 2900 cm-1 which are characteristic of (C-H) aliphatic frequencies, as well as 
an intense absorption band at 1716 cm-1 and 1720 cm-1 for 39 and 40, respectively, 
which could be attributed to the RCOOR functionality. 
 
The melting point of the newly synthesized G0 ligand (39) was recorded at 149-
153°C, higher than the melting points recorded for its component parts, the core (35) 
and the G0 wedge (36).  The elemental analysis was in close agreement to the 
calculated values for the G0 ligand, and mass spectrometry (Fig. 4.5) gave a 100% 
protonated molecular ion peak (i.e. m/z 593.3, [M+H]+) for the ligand, 39. 
 
 
 
Fig. 4.5: Mass spectrometry (ESI) of G0 ligand, 39. 
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4.4. Synthesis of dendritic complexes, 41 (G0) and 42 (G1) 
 
N N ORwedgeRwedgeO
Br
Br-Rwedge =
Br
OO
41 (G0)
42 (G1)
Pd
Cl Cl
N N ORwedgeRwedgeO
PdCl2(COD)/CH2Cl
O OCH3
O OCH3 OCH3O
/24 hrs, rt.
 
 
The reactions for the synthesis of 41 and 42 (equation (4.6)) were performed under 
an inert atmosphere using conditions described by Blom et al.22 for similar 
complexes.  The newly synthesized palladium complexes (41 and 42) of the α-
diimine ligands were prepared by treating a slight excess of the ligand with 
PdCl2(COD) in dry dichloromethane.  The reactions were allowed to stir for 24 hours 
at room temperature.  The products were isolated as yellow-orange solids in 
moderate to good yields of 58% and 73% for 41 and 42, respectively. 
 
4.4.1. 1H-NMR spectra of dendritic complexes, 41 (G0) and 42 (G1). 
 
The 1H-NMR spectra of the complexes (41 and 42) show similar peak shifts as is 
seen in the spectra of the dendritic ligands (39 and 40).  This is expected as the 
coordination of the palladium to the core could possibly only cause a shift in the 
…Eq. (4.6) 
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protons of the methyls bonded to the imines.  However, there are no significant shifts 
observed for these peaks. 
 
4.4.2. Infrared spectra, melting points and elemental analyses of dendritic 
complexes, 41 (G0) and 42 (G1). 
 
The infrared spectra of 41 and 42 show a characteristic medium intensity absorption 
band occurring at 1578 cm-1 and 1571 cm-1, respectively, which can be attributed to 
the imine functionality. This was lower than the attributed (C=Nimine) frequencies of 
the respective ligands, 39 and 40, which occur at 1640 cm-1 and 1639 cm-1, 
respectively.  These shifts are also reported by Blom et al.22 for similar compounds 
(i.e. a shift from 1640-1639 cm-1 for the ligands to 1579-1570 cm-1 for the 
complexes). The shifts are most likely due to the palladium withdrawing electron 
density from the ligands. 
 
Table 4.1: Absorption bands (cm-1) attributed to the imine functionalities observed in the IR 
spectra (using KBr pellets) of 39-42 compared to absorption bands (cm-1) observed by Blom 
et al.22 (in brackets) for similar compounds. 
Generation 
39-42 (Blom et al.22) 
Ligands Complexes 
G0 1638 (1640) 1578 (1579) 
G1 1636 (1639) 1571 (1570) 
 
 
The melting point determination revealed that the G0 complex (41) decomposed 
(without melting) above 290°C, proving that the product is not unreacted ligand 
(melting point = 149-153 °C), which further suggests complexation had occurred. 
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4.5. Radiolabelling studies 
 
The dendritic ligands, subsequent to their synthesis, were tested for their 
radiolabelling ability with 109Pd. The dendritic ligand (39 or 40) in an organic solution 
(ethanol, acetonitrile or dichloromethane) was reacted with [109Pd]PdCl2 in HCl/H2O. 
The reactions were heated at 41-55°C for 1-1.5 hours, after which the reaction 
mixtures were analysed using a HPLC coupled to a radiodetector. The HPLC 
chromatograms of the reactions using both ligands show no significant new peak 
similar to that of the cold complexes (a peak just below 5 minutes for both 41 and 42) 
in the 0 - 700 keV region. However, the chromatogram for the reaction using the G0 
ligand in dichloromethane shows a relatively small peak just above 21 minutes. This 
suggests that a radiolabelled species had formed. This peak could not be further 
analyzed as the nuclide had decayed too much overnight (i.e. there were no visible 
peaks in the chromatograms after radioanalysis was carried out the following day). 
The chromatograms show a peak at approximately 3 minutes which could be due to 
free [109Pd]PdCl2. HPLC-MS was also used to analyze the reaction mixture. 
However, no new information could be extracted. Gamma spectrum analysis shows 
that the 109Pd nuclide was present in the mixture for the reaction using the G0 ligand, 
however, it does not show whether the nuclide was free or part of a complex. 
 
4.6. Conclusion/Summary and Future work 
 
Two new dendritic poly(aryl)ether ligands were synthesized in moderate yields via a 
series of steps. These ligands were characterized using various spectroscopic and 
analytical techniques. The ligands were subsequently reacted with PdCl2(COD) to 
afford dendritic poly(aryl)ether complexes, which were also characterized. The 
ligands were tested for their radiolabelling ability with 109Pd (in the form of 109PdCl2) 
in different organic solvents. There is a currently unidentified peak in the HPLC 
chromatogram, found when analyzing the reaction mixture in dichloromethane as 
reaction solvent. This suggests that a radiolabelled species had formed. However, 
this peak could not be further analyzed due to the decay of 109Pd. Future works 
would include the synthesis of radiolabelled palladium(II) dendrimers in 
dichloromethane using synthesized 109PdCl2(COD). 
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Chapter 5: 
 
Experimental 
 
5.1. General Procedure 
 
5.1.1. Chemicals and radiochemicals 
 
All complexation reactions were carried out under nitrogen, using a glovebox 
(MBraun Unilab) or standard Schlenk line techniques under argon. The starting 
materials, thiosemicarbazide and 4,4-dimethyl-3-thiosemicarbazide, were purchased 
from Sigma-Aldrich Co. and were used as delivered.  Acetophenone, 2-furaldehyde, 
2-pyrrolecarboxaldehyde, 2-pyridinecarboxaldehyde, 3-pyridinecarboxaldehyde, 2-
acetylpyridine, 2-acetylfuran, 2-acetylpyrrole, 3-acetylpyridine and sodium acetate 
were also purchased from Sigma-Aldrich Co. and were used without any further 
purification.  Benzaldehyde was purchased from Merck and was used without any 
further purification.  All reaction solvents were AR grade, purchased from Kimix 
Chemicals.  The metal salts, gallium(III) chloride and gallium(III) nitrate, were both 
purchased from Sigma-Aldrich Co. The cation exchange resin was obtained from 
Bio-Rad. The gallium(III) chloride was stored in a glovebox under inert atmosphere.  
Reactions performed using gallium(III) chloride required the use of dry ethanol. 
Radiolabelling reactions were carried out in absolute ethanol stored over 4Å 
molecular sieves. 
 
Caution was taken when working with radioisotopes. For any work with an open 
radioactive source, gloves (long-cuffed), a full-length lab coat and close-toed shoes 
were worn. All radioisotopes were handled inside lead pots, and all radiolabelling 
experiments were performed behind lead-brick walls. 67Ga was produced at iThemba 
LABS, making use of the natZn(p,2n)66,67Ga nuclear reaction. After the target 
bombardment process, the radionuclidic impurity, 66Ga, having a much shorter half-
life (9.4 hours) than 67Ga (78.3 hours), was allowed to decay to an acceptable low 
level before the chemical separation process was started. The irradiated target was 
dissolved in 10M HCl and the solution was loaded onto an AmberChrom Cg-71 cd 
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synthetic absorbent resin, pre-equilibrated with 7M HCl. The column was then 
washed with 200 mL 7M HCl to remove the target material and other radionuclidic 
impurities.  Finally, the 67Ga was eluted with 25 mL 0.5M HNO3. The solution was 
evaporated to dryness and the activity re-dissolved in 6 mL 0.01M HCl to render 
[67Ga]GaCl3. A few labelling reactions were carried out using the acidic aqueous 
[67Ga]GaCl3 solution. However, a few others were also carried out using an acidic 
acetonic solution. This was prepared as follows: A 1 mL solution of [67Ga]GaCl3 in 
0.01M HCl was loaded on a small cation exchange resin column (70 mg AGMP-50 
resin, 200-400 mesh, H+ form, pre-equilibrated with 1 mL 0.1M HCl). Elution through 
the resin was facilitated by applying a small negative pressure inside the receiving 
vial. The resin was subsequently eluted with a mixture of 80% acetone in 0.15M HCl 
(0.5 mL), followed by 98% acetone in 0.05M HCl (0.5 mL). The latter eluate 
contained the bulk of the activity and was used in a few labelling reactions. All 
labelling reactions using [67Ga]GaCl3 were carried out in 2 mL glass vials 
(approximately 6 mm in diameter). The palladium(II) radioisotope, 109Pd, was 
produced at the South African Nuclear Energy Corporation (NECSA) at Pelindaba, 
making use of the 108Pd(n,g)109Pd nuclear reaction. The target bombardment 
process lasted 84 hours, with a cooling time of 47 hours and 45 minutes. 
 
5.1.2. Physical Measurements 
 
The Nuclear Magnetic Resonance (NMR) spectra were recorded on a Varian Unity 
XR400 (1H: 399.95 MHz), Varian Mercury XR300 (1H: 300.08 MHz, 13C{1H}: 75.46 
MHz) or Bruker Ultrashield 400 Plus (1H: 400.20 MHz) spectrometer at ambient 
temperature with tetramethylsilane (TMS) as an internal standard.  IR spectra were 
measured on a Perkin-Elmer Spectrum One FT-IR Spectrometer using KBr (4000-
400 cm-1) pellets.  Elemental analysis was carried out using a Fision EA 110 CHNS 
elemental analyzer and melting points were determined using a Kofler hot stage 
microscope (Riechart Thermover). Radioactivity measurements were carried out in a 
Vinten Isocal II Radionuclide Assay Calibrator, using the millicurie (mCi) as the 
radioactivity unit.  High Performance Liquid Chromatography (HPLC) was carried out 
on a Perkin Elmer Series 200 lc pump (for binary elution) using a Phenomenex Luna 
5μ C18 250x4.6 mm2 column and 2 mM ethylenediaminetetraacetic acid (EDTA) 
pH4: acetonitrile (MeCN) as the mobile phase.  A gradient elution method was 
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employed, whereby an 80: 20 (2 mM EDTA pH4: MeCN) mixture was used as the 
mobile phase for the first 5 minutes, followed by a gradual change to 40: 60 for the 
next 5 minutes, and thereafter maintaining this ratio for a further 5 minutes.  Finally, 
the ratio was changed to 100% MeCN over 5 minutes. The column outlet was 
coupled to a NaI (Tl) radioactivity detector, which in turn was connected to an 
ORTEC ratemeter and a high voltage power supply (1 kV). A Hewlett Packard 
HP3394 integrator was used to record chromatograms. An alternative HPLC system 
was also used, consisting of an Agilent 1100 Series pump, equipped with an HP 
1100 Series Control Module for binary gradient elution and a Rheodyne Model 7725 
injector. The same type of column was used. The column outlet was coupled to a 
Spectra Series UV100 detector, set at 254 nm, which, in turn, was coupled in series 
with a Carroll & Ramsey Model 105S-1 CsI(Tl) radioactivity detector. 
Chromatograms were recorded on a dual channel Chromatopac C-R8A from 
Shimadzu. An identical gradient elution programme to the one described above was 
used. Retention times of the cold complexes (detected by the UV detector and 
recorded on channel 1) were compared with those of the radiolabelled complexes 
(detected by the radioactivity detector and recorded on channel 2) in order to prove 
the authenticities of the latter. 
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5.2. Synthesis and Characterisation 
 
5.2.1. Synthesis of monthiosemicarbazone ligands. 
 
5.2.1.1. Synthesis of benzaldehyde thiosemicarbazone, 1.1 
 
N
H
N
S
NH2
a
a
b
b
b
 
1 
 
Warm ethanol (30 mL) was added to benzaldehyde (0.60 mL; 0.0059 mol.).  
Thiosemicarbazide (0.55 g; 0.0060 mol.) dissolved in warm water (30 mL) was 
added to the benzaldehyde/ethanol mixture.  The reaction mixture was refluxed at 
65C for 2 hours.  The reaction mixture was allowed to cool to room temperature 
before it was cooled further in ice.  A white product precipitated out of solution during 
cooling in an ice-bath.  The white precipitate was collected by suction filtration and 
was isolated as a white powder.  The white powder was recrystallized in aqueous 
ethanol (50%).  A pure white powder of 1 (0.55 g; 51 %) was yielded.  Melting point 
= 161-162C (lit. M.P. = 159C1).  Elemental analysis calculated for C8H9N3S: C, 
53.61; H, 5.06; N, 23.44; S, 17.89%.  Found: C, 53.60; H, 5.23; N, 23.76; S, 18.14%.  
1H-NMR (400 MHz, DMSO-d6):  7.42 ppm (m, 3H, Hb); 7.81 ppm (m, 2H, Ha); 7.98 
ppm (s, 1H, -HN-H); 8.09 ppm (s, 1H, -CH=N-); 8.19 ppm (s, 1H, -HN-H); 11.42 ppm 
(s, 1H, -NH-). FT-IR (KBr pellet):  (C=Nimine) 1591 cm-1 (s). 
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5.2.1.2. Synthesis of 2-furaldehyde thiosemicarbazone, 2.2 
 
N
H
N
S
NH2
O
a
b
c  
2 
 
Thiosemicarbazide (0.91 g; 0.010 mol) was dissolved in warm distilled water (50 
mL).  The thiosemicarbazide solution was added to an ethanolic solution (30 mL) of 
2-furaldehyde (0.83 mL; 0.010 mol).  The reaction mixture was allowed to reflux at 
60C for 24 hours.  The reaction mixture was allowed to cool to room temperature 
before it was put in an ice-bath to further cool.  An orange solid precipitated out of 
solution on cooling in the ice-bath.  The orange solid was collected by suction 
filtration and was washed with cold ethanol.  The product, 2, was isolated as an 
orange powder (0.69 g; 41%).  Melting point = 150-151 C (Lit. M.P. = 159 C3).  
Elemental analysis calculated for C6H7N3SO: C, 42.59; H, 4.17; N, 24.83; S, 
18.95%.  Found: C, 42.45; H, 4.11; N, 26.00; S, 19.12%.  1H-NMR (400 MHz, 
DMSO-d6):  6.63 ppm (s, 1H, Hb); 6.99 ppm (s, 1H, Ha); 7.61 ppm (s, 1H, -HN-H); 
7.81 ppm (s, 1H, Hc); 8.00 ppm (s, 1H, -CH=N-); 8.19 ppm (s, 1H, -HN-H); 11.41 
ppm (s, 1H, -NH-). FT-IR (KBr pellet):  (C=Nimine) 1583 cm-1 (s). 
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5.2.1.3. Synthesis of phenyl-4,4-dimethylthiosemicarbazone, 3.4 
 
N
H
N
S
N
a
a
b
b
b
 
3 
 
Benzaldehyde (0.18 mL; 0.0018 mol) was added to a round-bottom flask.  Ethanol 
(10 mL) was added to the flask and the mixture was stirred at room temperature.  
Ethanol (16 mL) was added to 4,4-dimethyl-3-thiosemicarbazide (0.20 g; 0.0017 mol) 
in a beaker.  The mixture in the beaker was heated to dissolve the 4,4-dimethyl-3-
thiosemicarbazide in the ethanol.  The 4,4-dimethyl-3-thiosemicarbazide solution 
was added dropwise to the flask containing the benzaldehyde in ethanol solution.  
The mixture turned yellow upon the dropwise addition of the 4,4-dimethyl-3-
thiosemicarbazide solution.  The reaction mixture was allowed to reflux at 90C for 5 
hours before it was cooled back to room temperature with stirring.  The reaction 
mixture was stirred overnight at room temperature.  A yellowish precipitate had 
formed overnight.  The reaction mixture was put in an ice-bath to further cool.  A 
white precipitate was seen to have formed and was collected by suction filtration.  
The white precipitate was washed with cold distilled water.  A white powder of 3 
(0.21 g; 60 %) was yielded.  Melting point = 155-160C (Lit. M.P. = 167-168C5).  
Elemental analysis calculated for C10H13N3S: C, 57.94; H, 6.32; N, 20.27; S, 
15.47%.  Found: C, 57.58; H, 6.21; N, 19.90; S, 15.31%.  1H-NMR (300 MHz, 
DMSO-d6):  3.29 ppm (s, 6H, -N(CH3)2); 7.40 ppm (m, 3H, Hb); 7.63 ppm (m, 2H, 
Ha); 8.17 ppm (s, 1H, -CH=N-); 10.81 ppm (s, 1H, -NH-). FT-IR (KBr pellet):  
(C=Nimine) 1599 cm-1 (w). 
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5.2.1.4. Synthesis of 3-pyridine thiosemicarbazone, 4. 
 
N
H
N
S
NH2
N
ab
c
d
 
4 
 
Ethanol (10 mL) was added to 3-pyridinecarboxaldehyde (0.84 mL; 0.0089 mol) in a 
round-bottom flask.  The mixture was allowed to stir at room temperature.  
Thiosemicarbazide (0.81 g; 0.0089 mol) proved to be insoluble in ethanol (30 mL), 
even upon heating.  The thiosemicarbazide in ethanol was added to the 3-
pyridinecarboxaldehyde in ethanol mixture as a suspension.  The reaction mixture 
was refluxed at 90-100C for 6 hours before it was allowed to cool to room 
temperature with stirring.  The reaction mixture was stirred for 3 days. A white 
precipitate had formed upon stirring at room temperature and the reaction mixture 
was put in an ice-bath to further cool.  The white precipitate was collected by suction 
filtration and was washed with cold distilled water.  The white powder that was 
collected was dried in an oven at 100C for 2 hours.  A white powder of 4 (1.4 g; 87 
%) was yielded.  Melting point = 212-213C (Lit. M.P. = 221-222C6).  Elemental 
analysis calculated for C7H8N4S: C, 46.65; H, 4.47; N, 31.09; S, 17.79%.  Found: C, 
46.66; H, 4.39; N, 30.07; S, 17.34%.  1H-NMR (400 MHz, DMSO-d6):  7.43 ppm (m, 
1H, Hc); 8.10 ppm (s, 1H, -CH=N-); 8.12 ppm (s, 1H, Hd); 8.26 ppm (m, 2H, -NH2); 
8.59 ppm (m, 1H, Hb); 8.95 ppm (s, 1H, Ha); 11.56 ppm (s, 1H, -NH-). FT-IR (KBr 
pellet):  (C=Nimine) 1591 cm-1 (m). 
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5.2.1.5. Synthesis of 2-formylpyridine thiosemicarbazone, 5.7 
 
N
H
N
S
NH2
N
a
b
c
d
 
5 
 
Ethanol (10 mL) was added to 2-pyridinecarboxaldehyde (0.95 mL; 0.010 mol) in a 
round-bottom flask.  The mixture was allowed to stir at room temperature.  Ethanol 
(30 mL) was added to thiosemicarbazide (0.91 g; 0.010 mol) in a beaker.  The 
thiosemicarbazide was a suspension in the ethanol.  The thiosemicarbazide 
suspension was added to the stirring 2-pyridinecarboxaldehyde/ethanol mixture in 
the flask.  The reaction mixture was allowed to reflux at 80-90C for 6 hours.  The 
reaction mixture was a milky-yellow colour.  After refluxing, the reaction mixture was 
cooled to room temperature and was stirred overnight.  The round-bottom flask was 
further cooled in an ice-bath.  A milky-yellow precipitate was formed, collected by 
suction filtration and washed with cold ethanol.  The product was dried in an oven at 
100C for 2 hours.  The product 5 (1.4 g; 79 %) was isolated as a white powder.  
Melting point = 206-207 C (Lit. M.P. = 197-198 C8). Elemental analysis 
calculated for C7H8N4S: C, 46.65; H, 4.47; N, 31.09; S, 17.79 %.  Found: C, 46.76; 
H, 4.38; N, 30.88; S, 17.84 %.  1H-NMR (300 MHz, DMSO-d6):  7.35 ppm (t, 1H, 3J 
= 7.45 Hz, Hb); 7.80 ppm (t, 1H, 3J = 7.38 Hz, Hc); 8.07 ppm (s, 1H, HN-H); 8.11 ppm 
(s, 1H, -CH=N-); 8.22 ppm (d, 2H, 3J = 7.99 Hz, Hd + HN-H); 8.56 ppm (d, 1H, 3J = 
4.85 Hz, Ha); 11.55 ppm (s, 1H, -NH-). FT-IR (KBr pellet):  (C=Nimine) 1588 cm-1 (m). 
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5.2.1.6. Synthesis of 2-acetylpyridinethiosemicarbazone, 6.9 
 
N
N
H
N
S
NH2
a
b
c
d
 
6 
 
Ethanol (5 mL) was added to 2-acetylpyridine (1.12 mL, 0.01 mol) in a round-bottom 
flask, followed by stirring of the mixture.  Thiosemicarbazide (0.9126 g, 0.01 mol.) 
was added to the round-bottom flask subsequent to the addition of more ethanol (15 
mL) to the stirring mixture.  Acetic acid (1 mL) was added followed by refluxing (at 
80-90 °C) of the reaction mixture for 5 hours.  The reaction solution was yellow 
during and after refluxing.  The reaction mixture was allowed to stir overnight at room 
temperature.  After stirring overnight, the reaction mixture was further cooled in an 
ice-bath.  This allowed for a yellow solid to be precipitated out of the solution.  The 
solid was collected using a Büchner funnel and was dried in an oven (at 100 °C).  A 
light-yellow powder of 6 (1.5771 g, 81 %) was isolated.  Melting point = 163-165 C 
(Lit. M.P. = 161-162 C9).  Elemental analysis calculated for C8H10N4S: C, 49.46; H, 
5.19; N, 28.84; S, 16.51 %.  Found: C, 49.15; H, 5.21; N, 29.16; S, 16.53 %.  1H-
NMR (400 MHz, DMSO-d6):  2.41 ppm (s, 3H, -CH3); 7.40 ppm (t, 1H, 3J = 6.03 Hz, 
Hb); 7.80 ppm (t, 1H, 3J = 7.93 Hz, Hc); 8.13 ppm (s, 1H, -HN-H); 8.38 ppm (s, 1H, -
HN-H); 8.42 ppm (d, 1H, 3J = 8.10 Hz, Hd); 8.60 ppm (d, 1H, 3J = 4.38 Hz, Ha); 10.29 
ppm (s, 1H, -NH-). FT-IR (KBr pellet):  (C=Nimine) 1600 cm-1 (m). 
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5.2.1.7. Synthesis of 2-acetylfuranthiosemicarbazone, 7.10 
 
N
H
N
S
NH2
O
a
b
c
 
7 
 
Ethanol (20 mL) was added to 2-acetylfuran (1.1012 g, 0.01 mol.) in a round-bottom 
flask.  The mixture was stirred to dissolve the 2-acetylpyridine.  Thiosemicarbazide 
(0.9118 g, 0.01 mol.) was added to the round-bottom flask subsequent to the 
addition of more ethanol (15 mL) to the stirring mixture.  Acetic acid (1 mL) was 
added followed by refluxing (at 80-90 °C) of the reaction mixture for 5 hours.  The 
reaction solution mixture was clear (with a slight yellow colour).  As refluxing 
continued the reaction solution became more yellow.  The reaction mixture was 
allowed to stir overnight at room temperature.  The reaction mixture was further 
cooled in an ice-bath but no precipitate formed.  The volume of the solvent (ethanol) 
was reduced on the rotary evaporator.  Hexane was added to the mixture, which 
afforded a white powder on addition of the hexane.  Hexane was added in excess 
and the mixture was allowed to stand overnight.  Yellow solids had formed overnight.  
The yellow solid of 7 (1.1953 g, 65 %) was collected.  The product 7 was 
recrystallized from ethanol/water.  Melting point = 74-77 C (Lit. M.P. = 108-110 
C10).  Elemental analysis calculated for C7H9N3SO: C, 45.88; H, 4.95; N, 22.93; S, 
17.50 %.  Found: C, 42.54; H, 5.34; N, 23.35; S, 17.03 %.  1H-NMR (400 MHz, 
DMSO-d6):  2.26 ppm (s, 3H, -CH3); 6.60 ppm (s, 1H, Hb); 7.10 ppm (s, 1H, Ha); 
7.69 ppm (s, 1H, -HN-H); 7.78 ppm (s, 1H, Hc); 8.24 ppm (s, 1H, -HN-H); 10.24 ppm 
(s, 1H, -NH-). FT-IR (KBr pellet):  (C=Nimine) 1591 cm-1 (m). 
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5.2.1.8. Synthesis of acetophenone thiosemicarbazone, 8.11 
 
N
H
N
S
NH2
a
a
b
b
b
 
8 
 
Ethanol (5 mL) was added to acetophenone (1.17 mL, 0.01 mol.) in a round-bottom 
flask, followed by stirring of the mixture.  Thiosemicarbazide (0.9134 g, 0.01 mol.) 
was added to the stirring mixture.  More ethanol (15 mL) followed by glacial acetic 
acid (1 mL) was added to the reaction mixture.  The reaction mixture was allowed to 
reflux (at 80-90 °C) for 5 hours, after which it was cooled to room temperature and 
stirred overnight.  During overnight stirring (at room temperature) a solid had formed.  
The reaction mixture was further cooled in ice for 1 hour, after which the which the 
solid was collected via suction filtration.  A white solid of 8 (0.8538 g, 44 %) was 
obtained.  The product 8 was recrystallized from ethanol/hexane.  Melting point = 
114-115 C (Lit. M.P. = 110 C11).  Elemental analysis calculated for C9H11N3S: C, 
55.93; H, 5.74; N, 21.74; S, 16.59 %.  Found: C, 55.58; H, 5.70; N, 23.10; S, 17.01 
%.  1H-NMR (400 MHz, DMSO-d6):  2.33 ppm (s, 3H, -CH3); 7.41 ppm (t, 3H, 3J = 
2.83 Hz, 3Hb); 7.95 ppm (m, 3H, 2Ha + -HN-H); 8.26 ppm (s, 1H, -HN-H); 10.21 ppm 
(s, 1H, -NH-). FT-IR (KBr pellet):  (C=Nimine) 1588 cm-1 (s). 
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5.2.1.9. Synthesis of 2-acetylpyrrole thiosemicarbazone, 9.12 
 
N
H
N
H
N
S
NH2
a
b c
1
2
 
9 
 
Thiosemicarbazide (0.4579 g, 5.0 mmol) was added to a round-bottom flask and was 
dissolved in methanol (15 mL), with heating.  Methanol (15 mL) was added to 2-
acetylpyrrole (0.5457 g, 5.0 mmol) in a beaker, and the resultant solution was added 
to the reaction flask.  Acetic acid (0.5 mL) was added followed by refluxing (at 80-90 
°C) of the reaction mixture for 4.5 hours.  The reaction mixture was allowed to cool to 
room temperature.  Water was added to the reaction mixture and was left overnight 
at just below 10 °C.  This allowed for a white solid to be precipitated out of the 
solution.  The solid was collected using a Büchner funnel and was dried under 
vacuum.  A white solid of 9 (0.3250 g, 36 %) was isolated.  Melting point = 169-172 
C (Lit. M.P. = 160-171 C12). Elemental analysis calculated for C7H10N4S: C, 
46.13; H, 5.53; N, 30.74; S, 17.59 %.  Found: C, 46.28; H, 5.57; N, 30.80; S, 18.41 
%. 1H-NMR (400 MHz, DMSO-d6):  2.15 ppm (s, 3H, -CH3); 6.04 ppm (t, 1H, 3J = 
3.62 Hz, Hb); 6.44 ppm (d, 1H, 3J = 2.28 Hz, Hc); 6.88 ppm (d, 1H, 3J = 2.18 Hz, Ha); 
8.08 ppm (s, 1H, -HN-H); 8.21 ppm (s, 1H, -HN-H); 9.97 ppm (s, 1H, -N2H-); 11.35 
ppm (s, 1H, -N1H-). FT-IR (KBr pellet):  (C=Nimine) 1589 cm-1 (m). 
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5.2.1.10. Synthesis of 2-acetylpyridine-4,4-dimethylthiosemicarbazone, 10.3 
 
N
N
H
N
S
N
a
b
c
d
 
10 
 
A mixture of 4,4-dimethylthiosemicarbazide (0.2083 g, 1.68 mmol) in aqueous (19 
mL) 5 % acetic acid (1 mL) was stirred at 50-55 °C until a transparent solution was 
formed.  The mixture was placed under an inert atmosphere and 2-acetylpyridine 
(0.19 mL, 1.68 mmol) in aqueous 5 % acetic acid (0.6 mL) was added dropwise to 
the stirring mixture over 5 minutes.  Yellow solids were observed to have precipitated 
out of solution upon addition of the 2-acetylpyridine solution.  The resultant mixture 
was stirred for 4 hours.  After cooling to room temperature, the yellow solid was 
collected by suction filtration and washed with some cold ethanol followed by diethyl 
ether.  A yellow powder of 10 (0.2071 g, 56 %) was isolated.  Melting point = 147-
149 C (Lit. M.P. = 148-150 C13). Elemental analysis calculated for C10H14N4S: C, 
54.03; H, 6.35; N, 25.20; S, 14.42 %.  Found: C, 54.18; H, 6.39; N, 25.31; S, 15.82 
%. NMR data was shown to contain a mixture of three isomers; E, E' and Z. 1H-
NMR: E isomer (400 MHz, CDCl3):  2.65 (3H, s, CH3), 3.48 (6H, m, N(CH3)2), 7.31 
(1H, m, Hc), 7.54 (1H, m, Hd), 7.78 (1H, m, Hb), 8.46 (1H, br s, NH), 8.73 (1H, m, Ha); 
E' isomer (400 MHz, CDCl3):  2.41 (3H, s, CH3), 3.48 (6H, m, N(CH3)2), 7.25 (1H, 
m, Hc), 7.67 (1H, m, Hb), 7.96 (1H, m, Hd), 8.57 (1H, m, Ha), 14.82 (1H, br s, NH); Z 
isomer (400 MHz, CDCl3):  2.55 (3H, s, CH3), 3.48 (6H, m, N(CH3)2), 7.38 (1H, m, 
Hc), 7.61 (1H, m, Hd), 7.92 (1H, m, Hb), 8.63 (1H, m, Ha), 15.51 (1H, br s, NH). FT-IR 
(KBr pellet):  (C=Nimine) 1582 cm-1 (w). 
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5.2.1.11. Synthesis of 2-formylpyridine-4,4-dimethylthiosemicarbazone, 11.14 
 
N
N
H
N
S
N
a
b
c
d
 
11 
 
A mixture of 4,4-dimethylthiosemicarbazide (0.2074 g, 1.68 mmol) in water (15 mL) 
was stirred at 50-55 °C until a transparent solution was formed. Pyridine-2-
carboxaldehyde (0.19 mL, 1.68 mmol) was added, dropwise, to the stirring solution.  
The reaction mixture gradually changed from a clear to a yellow/orange solution 
upon addition of the 2-pyridinecarboxaldehyde. The reaction mixture was allowed to 
stir overnight at room temperature.  Light-yellow solids were observed to have 
formed after stirring overnight. The solids were collected by suction filtration and 
were dried in vacuo.  A light-yellow powder of 11 (0.2078 g, 59 %) was isolated.  
Melting point = 126-128 C (Lit. M.P. = 126-129 C14). Elemental analysis 
calculated for C9H12N4S: C, 51.90; H, 5.81; N, 26.90; S, 15.39 %.  Found: C, 52.14; 
H, 5.86; N, 27.19; S, 15.62 %. 1H-NMR (300 MHz, CDCl3):  3.48 ppm (6H, s, 
N(CH3)2), 7.37 ppm (1H, t, 3J = 7.63 Hz, Hc), 7.47 ppm (1H, d, 3J = 7.95 Hz, Hd), 7.50 
ppm (1H, s, -CH=N-), 7.88 ppm (1H, t, 3J = 7.77 Hz, Hb), 8.63 ppm (1H, d, 3J = 4.40 
Hz, Ha), 15.10 ppm (1H, s, NH). FT-IR (KBr pellet):  (C=Nimine) 1592 cm-1 (s). 
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5.2.1.12. Synthesis of 2-acetylpyrrole-4,4-dimethylthiosemicarbazone, 12. 
 
N
H
N
H
N
S
N
a
b c
2
1
 
12 
 
A mixture of 4,4-dimethylthiosemicarbazide (0.2035 g, 1.68 mmol) in water (15 mL) 
was stirred at 50-55 °C until a transparent solution was formed. Glacial acetic acid (6 
drops) was added to the mixture, followed by the dropwise addition of a methanolic 
solution (1 mL) of 2-acetylpyrrole (0.1892 g, 1.68 mmol).  The reaction mixture was 
stirred for 5 hours at room temperature and was stored at -16 °C for 24 hours.  White 
solids were observed to have formed, were collected by suction filtration and were 
dried in vacuo.  A white powder of 12 (0.1456 g, 41 %) was isolated.  Melting point 
= 101-103 C. Elemental analysis calculated for C9H14N4S: C, 51.40; H, 6.71; N, 
26.64; S, 15.25 %.  Found: C, 51.78; H, 6.77; N, 27.70; S, 15.51 %. Mass 
Spectrometry (EI+): m/z 211.3 (100%, [M+H]+).  13C-NMR (75 MHz, CDCl3):  17.8, 
40.2, 111.4, 117.3, 124.7, 125.4, 135.5, 182.5.  1H-NMR (300 MHz, CDCl3):  2.53 
ppm (3H, s, CH3), 3.36 ppm (6H, s, N(CH3)2), 6.40 ppm (1H, t, 3J = 3.36 Hz, Hb), 6.85 
ppm (1H, d, 3J = 2.25 Hz, Hc), 7.20 ppm (1H, t, 3J = 2.12 Hz, Ha), 12.08 ppm (1H, br 
s, -N2H-), 12.97 ppm (1H, br s, -N1H-). FT-IR (KBr pellet):  (C=Nimine) 1615 cm-1 (m). 
 
5.2.1.13. Synthesis of 2-formylpyrrole-4,4-dimethylthiosemicarbazone, 13.15 
 
N
H
N
H
N
S
N
a
b c
2
1
 
13 
 
A mixture of 4,4-dimethylthiosemicarbazide (0.199 g, 1.68 mmol) in water (15 mL) 
was stirred at 50-55 °C until a transparent solution was formed.  A methanolic 
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solution (1 mL) of 2-pyrrolecarboxaldehyde (0.166 g, 1.68 mmol) was added 
dropwise.  The reaction mixture was stirred for 3 days at room temperature.  Solids 
were observed to have formed during the stirring process and were collected by 
suction filtration.  A cream solid of 13 (0.26 g, 80 %) was isolated.  Melting point = 
76-79 C (Lit. M.P. = 102 C15). Elemental analysis calculated for C8H12N4S: C, 
48.96; H, 6.16; N, 28.55; S, 16.34 %.  Found: C, 48.81; H, 6.21; N, 28.96; S, 17.13 
%. 1H-NMR (400 MHz, CDCl3):  3.36 ppm (6H, s, N(CH3)2), 6.39 ppm (1H, t, 3J = 
3.38 Hz, Hb), 6.84 ppm (1H, d, 3J = 2.26 Hz, Hc), 7.20 ppm (2H, m, -CH=N- + Ha), 
11.36 ppm (1H, br s, -N2H-), 12.90 ppm (1H, br s, -N1H-). FT-IR (KBr pellet):  
(C=Nimine) 1628 cm-1 (m). 
 
5.2.1.14. Synthesis of 2-acetylpyrrole thiosemicarbazone, 14.16 
 
N
H
N
H
N
S
NH2
a
b c
2
1
 
14 
 
Thiosemicarbazide (0.4797 g, 5.0 mmol) was added to a round-bottom flask and was 
dissolved in methanol (15 mL), with heating.  Methanol (15 mL) was added to 2-
pyrrolecarboxaldehyde (0.5053 g, 5.0 mmol) in a beaker, and the resultant solution 
was added, dropwise, to the reaction flask.  The reaction mixture was allowed to 
refux (at 70 °C) for 24 hours.  The reaction mixture was allowed to cool to room 
temperature.  Water was added to the reaction mixture and was left overnight at just 
below 10 °C.  This allowed for a purple solid to precipitate out of the solution.  The 
solid was collected using a Büchner funnel and was dried under vacuum.  A purple 
solid of 14 (0.70 g, 83 %) was isolated.  Melting point = 204-207 C (Lit. M.P. = 195-
197 C16). Elemental analysis calculated for C6H8N4S: C, 42.84; H, 4.79; N, 33.31; 
S, 19.06 %.  Found: C, 42.58; H, 4.85; N, 33.10; S, 19.17 %. 1H-NMR (400 MHz, 
DMSO-d6):  6.06 ppm (t, 1H, 3J = 3.58 Hz, Hb); 6.34 ppm (d, 1H, 3J = 2.28 Hz, Hc); 
6.90 ppm (d, 1H, 3J = 2.14 Hz, Ha); 7.80 ppm (s, 1H, -CH=N-), 7.85 ppm (s, 1H, -HN-
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H); 7.95 ppm (s, 1H, -HN-H); 11.16 ppm (s, 1H, -N2H-); 11.28 ppm (s, 1H, -N1H-). 
FT-IR (KBr pellet):  (C=Nimine) 1617 cm-1 (s). 
 
5.2.1.15. Synthesis of 2-formylfuran-4,4-dimethylthiosemicarbazone, 15.17 
 
O
N
H
N
S
N
a
b c
 
 
15 
 
A mixture of 4,4-dimethylthiosemicarbazide (0.208 g, 1.70 mmol) in water (15 mL) 
was stirred until a transparent solution was formed.  A solution of 2-furaldehyde 
(0.141 mL, 1.70 mmol) was added dropwise.  The reaction mixture was stirred for 24 
hours at room temperature.  Solids were observed to have formed during the stirring 
process and were collected by suction filtration.  A white solid of 15 (0.28 g, 84 %) 
was isolated.  Melting point = 141-143 C. Elemental analysis calculated for 
C8H11N3SO: C, 48.71; H, 5.62; N, 21.30; S, 16.26 %.  Found: C, 48.98; H, 5.70; N, 
22.14; S, 16.76 %. 1H-NMR (300 MHz, DMSO-d6):  3.23 ppm (6H, s, N(CH3)2), 6.58 
ppm (1H, br s, Hb), 6.78 ppm (1H, d, 3J = 3.78 Hz, Hc), 7.76 ppm (1H, br s, Ha), 8.08 
ppm (1H, s, -CH=N-), 10.77 (1H, s, -NH-). FT-IR (KBr):  (C=Nimine) 1617 cm-1 (m). 
 
5.2.1.16. Synthesis of 2-acetylfuran-4,4-dimethylthiosemicarbazone, 16. 
 
O
N
H
N
S
N
a
b c
 
16 
 
A solution of 4,4-dimethylthiosemicarbazide (0.205 g, 1.70 mmol) in water (15 mL) 
was stirred until a transparent solution was formed.  A solution of 2-acetylfuran 
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(0.189 g, 1.70 mmol) in methanol (1 mL) was added dropwise, along with glacial 
acetic acid (6 drops).  The reaction mixture was stirred for 24 hours at room 
temperature.  Solids were observed to have formed during the stirring process and 
were collected by suction filtration.  A yellow powder of 16 (0.24 g, 66 %) was 
isolated.  Melting point = 141-143 C. Elemental analysis calculated for 
C9H13N3SO: C, 51.16; H, 6.20; N, 19.89; S, 15.18 %.  Found: C, 51.48; H, 6.42; N, 
20.15; S, 16.29 %. Mass Spectrometry (EI+): m/z 212.3 (100%, [M+H]+). 13C-NMR 
(75 MHz, CDCl3):  17.1, 43.1, 111.8, 113.0, 113.8, 121.3, 144.0, 146.0. 1H-NMR 
(300 MHz, CDCl3):  2.46 ppm (1H, s, -C(CH3)=N-), 3.39 ppm (6H, s, N(CH3)2), 6.56 
ppm (1H, t, 3J = 3.54 Hz, Hb), 6.02 ppm (1H, br s, Hc), 7.62 ppm (1H, d, 3J = 1.75 Hz, 
Ha). FT-IR (KBr):  (C=Nimine) 1638 cm-1 (w). 
 
5.2.1.17. Synthesis of 3-formylpyridine-4,4-dimethylthiosemicarbazone, 17. 
 
N
N
H
N
S
N
ab
c
d
 
17 
 
A solution of 4,4-dimethylthiosemicarbazide (0.205 g, 1.70 mmol) in water (15 mL) 
was stirred until a transparent solution was formed.  A solution of 3-
pyridinecarboxaldehyde (0.16 mL, 1.7 mmol) was added dropwise.  The reaction 
mixture was stirred for 24 hours at room temperature.  Solids were observed to have 
formed during the stirring process and were collected by suction filtration.  A light-
yellow solid of 17 (0.30 g, 85 %) was isolated.  Melting point = 148-150 C. 
Elemental analysis calculated for C9H12N4S: C, 51.90; H, 5.81; N, 26.90; S, 15.39 
%.  Found: C, 52.18; H, 5.94; N, 27.13; S, 15.66 %. Mass Spectrometry (EI+): m/z 
209.3 (100%, [M+H]+). 13C-NMR (75 MHz, CDCl3):  12.5, 44.1, 123.3, 133.1, 144.0, 
147.5, 150.1, 152.2, 183.1. 1H-NMR (300 MHz, CDCl3):  3.45 ppm (6H, s, N(CH3)2), 
7.31 ppm (1H, t, 3J = 7.45 Hz, Hc), 7.70 ppm (1H, s, -CH=N-), 7.92 ppm (1H, d, 3J = 
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7.89 Hz, Hb), 8.58 ppm (1H, d, 3J = 7.38 Hz, Hd), 8.79 ppm (1H, s, Ha), 8.94 ppm (1H, 
s, NH). FT-IR (KBr pellet):  (C=Nimine) 1605 cm-1 (m). 
 
5.2.1.18. Synthesis of 3-acetylpyridine-4,4-dimethylthiosemicarbazone, 18. 
 
N
N
H
N
S
N
ab
c
d
 
18 
 
A solution of 4,4-dimethylthiosemicarbazide (0.206 g, 1.70 mmol) in water (15 mL) 
was stirred until a transparent solution was formed.  A solution of 3-acetylpyridine 
(0.18 mL, 1.7 mmol) was added dropwise, along with glacial acetic acid (10 drops).  
The reaction mixture was stirred for 24 hours at room temperature.  Solids were 
observed to have formed during the stirring process and were collected by suction 
filtration.  A yellow powder of 18 (0.22 g, 59 %) was isolated.  Melting point = 100-
102 C. Elemental analysis calculated for C10H14N4S: C, 54.03; H, 6.35; N, 25.20; 
S, 14.42 %.  Found: C, 54.28; H, 6.42; N, 25.41; S, 15.09 %. Mass Spectrometry 
(EI+): m/z 223.3 (100%, [M+H]+). 13C-NMR (75 MHz, CDCl3):  43.8, 123.7, 130.1, 
133.6, 139.2, 149.0, 151.0, 181.6. 1H-NMR (300 MHz, CDCl3):  2.27 ppm (1H, s, -
C(CH3)=N-), 3.43 ppm (6H, s, N(CH3)2), 7.35 ppm (1H, t, 3J = 7.51 Hz, Hc), 8.00 ppm 
(1H, d, 3J = 7.42 Hz, Hb), 8.39 ppm (1H, s, NH), 8.59 ppm (1H, d, 3J = 7.97 Hz, Hd), 
8.94 ppm (1H, d, 3J = 4.35 Hz, Ha). FT-IR (KBr pellet):  (C=Nimine) 1615 cm-1 (m). 
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5.2.1.19. Synthesis of N-phenylhydrazinecarbothioamide,19.18 
 
 
N
H
H2N
N
H
S
 
 
19 
 
Hydrazine hydrate (0.75 mL, 15 mmol) was added to a solution of phenyl 
isothiocyanate (1.8 mL, 10 mmol) and ethanol (60 mL).  The reaction mixture was 
allowed to stir for 60 minutes as white crystals precipitated out of the reaction 
mixture.  The white crystals were collected on a Büchner funnel and washed with 
cold ethanol.  The product was dried and 1.8 g (72 % yield) of the white crystalline 
product 19 was collected.  Melting point = 132-136 C(Lit. M.P. = 135 C18). 1H-
NMR (300 MHz, DMSO-d6):  4.85 ppm (br s, 2H, -NH2), 7.07 ppm (t, 1H, 3J = 7.39 
Hz, Ar-H[p]), 7.27 ppm (m, 2H, Ar-H[m]), 7.63 ppm (d, 2H, 3J = 7.82 Hz, Ar-H[o]), 
7.80 ppm (br s, 1H, -NH-CS-), 8.96 ppm (br s, 1H, -NH-Ph). 
 
5.2.1.20. Synthesis of 2-formylpyridine-4-phenylthiosemicarbazone, 20.19 
 
N
N
H
N
S
H
N
a
b
c
d e
e
f
f
f
1 2
 
20 
 
A solution of 2-pyridinecarboxaldehyde (0.12 mL, 1.2 mmol) was added, dropwise, to 
a suspension of N-phenylhydrazinecarbothioamide, 19, (0.206 g, 1.20 mmol) in 
ethanol (20 mL). The reaction mixture was allowed to reflux for 24 hours and was 
cooled to room temperature. Water (20 mL) was added to the reaction mixture to 
precipitate out the product. A white powder precipitated out of solution and was 
collected. A white powder of 20 (0.10 g, 33 %) was isolated. Melting point = 204-
206 C (Lit. M.P. = 212-214 C19). Elemental analysis calculated for C13H12N4S: C, 
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60.91; H, 4.72; N, 21.86; S, 12.51 %.  Found: C, 61.29; H, 4.75; N, 22.43; S, 12.73 
%. 1H-NMR (300 MHz, DMSO-d6):  7.22 ppm (1H, t, 3J = 7.36 Hz, Hb), 7.38 ppm 
(3H, t, 3J = 8.01 Hz, Hf), 7.59 ppm (2H, d, 3J = 7.57 Hz, He), 7.84 ppm (1H, t, 3J = 
7.75 Hz, Hc), 8.22 ppm (1H, s, -CH=N-), 8.40 ppm (1H, d, 3J = 8.00 Hz, Hd), 8.59 
ppm (1H, d, 3J = 4.84 Hz, Ha), 10.17 ppm (1H, s, N2H), 11.91 ppm (1H, s, N1H). FT-
IR (KBr pellet):  (C=Nimine) 1597 cm-1 (m). 
 
5.2.1.21. Synthesis of 2-acetylpyridine-4-phenylthiosemicarbazone, 21.19 
 
N
N
H
N
S
H
N
a
b
c
d e
e
f
f
f
1 2
 
21 
 
A solution of 2-acetylpyridine (0.13 mL, 1.2 mmol) was added, dropwise, to a 
suspension of N-phenylhydrazinecarbothioamide, 19, (0.200 g, 1.20 mmol) in 
ethanol (20 mL) in the presence of glacial acetic acid (0.5 mL). The reaction mixture 
was allowed to reflux for 24 hours and was cooled to room temperature. Water (20 
mL) was added to the reaction mixture to precipitate out the product. A light-yellow 
solid precipitated out of solution and was collected. A light-yellow solid of 21 (0.20 g, 
63 %) was isolated.  Melting point = 173-177 C (Lit. M.P. = 190-192 C19). 
Elemental analysis calculated for C14H14N4S: C, 62.20; H, 5.22; N, 20.72; S, 11.86 
%.  Found: C, 62.08; H, 5.30; N, 20.59; S, 11.62 %. 1H-NMR (300 MHz, DMSO-d6):  
3.21 ppm (3H, s, CH3), 7.23 ppm (1H, t, 3J = 7.35 Hz, Hb), 7.40 ppm (3H, t, 3J = 7.99 
Hz, Hf), 7.59 ppm (2H, d, 3J = 7.57 Hz, He), 7.82 ppm (1H, t, 3J = 7.74 Hz, Hc), , 8.50 
ppm (1H, d, 3J = 8.02 Hz, Hd), 8.60 ppm (1H, d, 3J = 4.84 Hz, Ha), 10.12 ppm (1H, s, 
N2H), 10.55 ppm (1H, s, N1H). FT-IR (KBr pellet):  (C=Nimine) 1588 cm-1 (w). 
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5.2.2. Synthesis of dithiosemicarbazone ligands. 
 
5.2.2.1. Synthesis of ethane-1,2-dithiosemicarbazide, 22.20 
 
H2N
H
N
S
H
N
N
H
S
N
H
NH2
21
2 1
 
22 
 
Ethane-1,2-diamine (1.67 mL, 0.025 mol) was added to a 250 mL round bottom 
flask, followed by an aqueous (40 mL) solution of NaOH (2.06 g, ~0.050 mol) and 
CS2 (4.50 mL, 0.075 mol).  The reaction mixture was stirred for 4 hours, after which 
sodium chloroacetate (5.83 g, 0.050 mol) was added. The resultant mixture was 
stirred for a further 19 hours.  The reaction mixture was acidified with 2M HCl (5 mL), 
followed by the addition of H2NNH2 (10.8 mL, 0.35 mol).  The reaction mixture was 
refluxed for 2 hours and cooled to room temperature.  White solids were seen to 
have precipitated and the flask was placed in an ice bath to promote further 
precipitation.  The white solids were collected by suction filtration and were washed 
with water, ethanol and diethyl ether.  White solids of 22 (2.1041 g, 40 %) were 
isolated.  Melting point = 213-214 C (Lit. M.P. = 212-214 C20).  1H-NMR (300 
MHz, DMSO-d6):  3.61 ppm (s, 4H, -(CH2)2-); 4.39 ppm (s, 4H, 2 -NH2); 7.91 ppm 
(s, 2H, 2-N2H-); 8.52 ppm (s, 2H, 2-N1H-).  
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5.2.2.2. Synthesis of 2-formylpyridine ethane-1,2-dithiosemicarbazone, 23. 
 
N
N
H
N
S
H
N
N
H
S
N
H
N
N
a
b
c
d
a
b
c
d
12
21
 
23 
 
Ethane-1,2-dithiosemicarbazide (0.4041 g, 1.93 mmol) was dissolved in 
dimethylformamide (20 mL) and 2-pyridinecarboxaldehyde (0.365 mL, 3.84 mmol) 
was added to the flask.  A white milky solution was observed before the addition of 
2-pyridinecarboxaldehyde, after which the solution became a clear yellow.  The 
reaction mixture was refluxed for 5 hours at 100-110 °C.  The reaction mixture was 
allowed to cool to room temperature, after which water was added to precipitate a 
light-yellow solid.  The yellow solid (0.6026 g, 80 %) of 23 was collected by suction 
filtration.  Melting point = 227-229 C.  Elemental analysis calculated for 
C16H18N8S2: C, 49.72; H, 4.69; N, 28.99; S, 16.59 %.  Found: C, 46.62 ; H, 5.14; N, 
28.59; S, 15.27 %.  1H-NMR (400 MHz, DMSO-d6):  3.88 ppm (s, 4H, -(CH2)2-); 7.38 
ppm (t, 2H, 3J = 6.43 Hz, 2Hb); 7.79 ppm (t, 2H, 3J = 7.65 Hz, 2Hc); 8.12 ppm (s, 2H, 
2-CH=N-); 8.28 ppm (d, 2H, 3J = 7.83 Hz, 2Hd); 8.56 ppm (d, 2H, 3J = 3.68 Hz, 2Ha); 
8.80 ppm (s, 2H, 2-N2H-); 11.80 ppm (s, 2H, 2-N1H-). FT-IR (KBr pellet):  (C=Nimine) 
1587 cm-1 (m). 
 
Alternate Synthesis: Ethane-1,2-dithiosemicarbazide (0.4011 g, 1.93 mmol) was 
added to ethanol (40 mL) as a suspension followed by 2-
formylpyridinecarboxaldehyde (~0.37 mL, 3.85 mmol).  The reaction mixture was 
refluxed (at 90°C)  for 24 hours.  The reaction was allowed to cool to room 
temperature and the solids that were present in the reaction flask was collected via 
suction filtration.  Light-yellow solids of 23 (0.6669 g, 89 %) were isolated.  1H-NMR 
(300 MHz, DMSO-d6):  3.88 ppm (s, 4H, -(CH2)2-); 7.34 ppm (t, 2H, 3J = 6.42 Hz, 
2Hb); 7.74 ppm (t, 2H, 3J = 7.65 Hz, 2Hc); 8.10 ppm (s, 2H, 2-CH=N-); 8.22 ppm (d, 
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2H, 3J = 7.84 Hz, 2Hd); 8.54 ppm (d, 2H, 3J = 3.69 Hz, 2Ha); 8.73 ppm (s, 2H, 2-N2H-
); 11.69 ppm (s, 2H, 2-N1H-). 
 
5.2.2.3. Synthesis of 2-acetylpyridine ethane-1,2-dithiosemicarbazone, 24.21 
 
N
N
H
N
S
H
N
N
H
S
N
H
N
N
a
b
c
d
a
b
c
d
12
21
 
24 
 
Ethylene dithiosemicarbazide (0.2047 g, 0.96 mmol) was dissolved in 
dimethylformamide (10 mL) and 2-acetylpyridine (0.22 mL, 1.92 mmol) was added to 
the flask, after which acetic acid (0.5 mL) was added.  The reaction mixture was 
refluxed for 5 hours at 110-120 °C.  The reaction mixture was allowed to cool to 
room temperature, after which water was added.  The reaction mixture was left 
overnight at below 10 °C.  A pale yellow solid (0.1695 g, 43 %) of 24 was observed 
and was collected by suction filtration.  Melting point = 196-199 C (Lit. M. P. = 214-
216 °C21).  Elemental analysis calculated for C18H22N8S2: C, 52.15; H, 5.35; N, 
27.03; S, 15.47 %.  Found: C, 52.36; H, 5.27; N, 27.47; S, 15.65 %.  1H-NMR (400 
MHz, DMSO-d6):  2.42 ppm (s, 6H, 2-CH3); 3.93 ppm (s, 4H, -(CH2)2-); 7.39 ppm (t, 
2H, 3J = 5.87 Hz, 2Hb); 7.73 ppm (t, 2H, 3J = 8.04 Hz, 2Hc); 8.40 ppm (d, 2H, 3J = 
8.06 Hz, 2Hd); 8.60 ppm (d, 2H, 3J = 4.73 Hz, 2Ha); 8.80 ppm (s, 2H, 2-N2H-); 10.43 
ppm (s, 2H, 2-N1H-). FT-IR (KBr pellet):  (C=Nimine) 1582 cm-1 (m). 
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5.2.3. Synthesis of gallium(III) thiosemicarbazones. 
 
5.2.3.1. Synthesis of gallium(III) 2-acetylpyridinethiosemicarbazone, 25.22 
 
N
N
N
S
NH2
a
b
c
d
Ga
Cl Cl  
25 
 
The reaction was performed under an inert atmosphere. A solution of GaCl3 (0.48 g, 
2.6 mmol) in dry ethanol (4 mL) was added, dropwise over a period of 10 minutes, to 
a stirring solution of ligand 6 (0.101 g, 0.515 mmol) in dry ethanol (12 mL).  The 
reaction mixture was refluxed for 1 hour and was allowed to cool to room 
temperature. Yellow solids of 25 (0.092 g, 54 %) were observed to have formed. 
Melting point = 236-239 C. Elemental analysis calculated for C8H9N4SGaCl2: C, 
28.76; H, 2.72; N, 16.77; S, 9.60 %.  Found: C, 28.75; H, 2.76; N, 16.68; S, 8.54 %. 
Mass Spectrometry (EI+): m/z 333.7 (100%, [M]+). 1H-NMR (400 MHz, DMSO-d6):  
2.72 ppm (3H, s, CH3), 7.28 ppm (2H, s, NH2), 7.90 ppm (1H, t, 3J = 5.35 Hz, Hc), 
8.16 ppm (1H, d, 3J = 8.00 Hz, Hd), 8.37 ppm (1H, t, 3J = 7.83 Hz, Hb), 9.02 ppm (1H, 
d, 3J = 5.34 Hz, Ha). FT-IR (KBr pellet):  (C=Nimine) 1603 cm-1 (m), 1558 cm-1 (s). 
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5.2.3.2. Synthesis of gallium(III) 2-acetylpyridine-4,4-dimethylthiosemicarbazone, 
26.22 
 
N
N
N
S
N
a
b
c
d
Ga
Cl Cl  
26 
 
The reaction was performed under an inert atmosphere. A solution of GaCl3 (0.771 
g, 4.38 mmol) in dry ethanol (5 mL) was added, dropwise over a period of 10 
minutes, to a stirring solution of ligand 10 (0.169 g, 0.758 mmol) in dry ethanol (20 
mL). During addition of the gallium solution a yellow precipitate appeared. The 
reaction mixture was stirred for 2 hours. The precipitate was filtered, yielding a 
yellow solid, 26 (0.16 g, 58 %). Melting point = 251-254 °C (Lit. M. P. > 250 °C23). 
Elemental analysis calculated for C10H13N4SGaCl2: C, 33.19; H, 3.62; N, 15.48; S, 
8.86 %. Found: C, 32.81; H, 3.68; N, 15.03; S, 6.57 %. Mass Spectrometry (EI+): 
m/z 361.9 (100%, [M]+). 1H-NMR (400 MHz, DMSO-d6):  2.77 ppm (3H, s, CH3), 
3.31 ppm (6H, s, N(CH3)2), 7.57 ppm (1H, t, 3J = 5.32 Hz, Hc), 7.92 ppm (1H, d, 3J = 
5.19 Hz, Hd), 8.20 ppm (1H, m, Hb), 8.25 ppm (1H, m, Ha). FT-IR (KBr pellet):  
(C=Nimine) 1601 cm-1 (m), 1553 cm-1 (s). 
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5.2.3.3. Synthesis of gallium(III) 2-formylpyridine-4,4-dimethylthiosemicarbazone, 27. 
 
N
N
N
S
N
a
b
c
d
Ga
Cl Cl  
27 
 
The reaction was performed under an inert atmosphere. A solution of GaCl3 (0.649 
g, 3.69 mmol) in dry ethanol (5 mL) was added, dropwise over a period of 10 
minutes, to a stirring solution of ligand 11 (0.154 g, 0.737 mmol) in dry ethanol (20 
mL). During addition of the gallium solution a yellow precipitate appeared, but the 
reaction became a yellow solution after further stirring. The reaction mixture was 
refluxed for 1.5 hours and was allowed to cool to room temperature. All the solvent 
was removed yielding a light-yellow crystalline solid, 27 (0.19 g, 75 %).  Melting 
point = 116-120 °C.  Elemental analysis calculated for C9H11N4SGaCl2:  C, 31.07; 
H, 3.19; N, 16.10; S, 9.22 %.  Found: C, 30.30; H, 3.25; N, 15.07; S, 7.05 %. Mass 
Spectrometry (EI+): m/z 347.9 (100%, [M]+).  1H-NMR (400 MHz, DMSO-d6):  3.27 
ppm (6H, s, N(CH3)2), 7.76 ppm (1H, t, 3J = 5.34 Hz, Hc), 7.86 ppm (1H, d, 3J = 7.83 
Hz, Hd), 8.27 ppm (1H, t, 3J = 7.74 Hz, Hb), 8.47 ppm (1H, s, -CH=N-), 8.80 ppm (1H, 
d, 3J = 5.26 Hz, Ha). FT-IR (KBr pellet):  (C=Nimine) 1606 cm-1 (m), 1566 cm-1 (s). 
 
5.2.4. Synthesis of radiolabelled gallium(III) thiosemicarbazones. 
 
For the general synthesis of the radiolabelled gallium(III) thiosemicarbazones, an 
acidic solution of [67Ga]GaCl3 in 0.01M HCl (30 μL, 1.17-1.70 mCi) was firstly 
transferred to a glass vial.  Acetonitrile (50 μL) was added to the vial and the mixture 
was evaporated to dryness using a flow of N2 gas and heat.  Acetonitrile (100 μL) 
was again added to the residue and the evaporation step was repeated.  The activity 
of [67Ga]GaCl3 was again measured and no significant loss of activity was observed.  
Alternatively, an acidic acetonic solution of [67Ga]GaCl3 (30 μL, 2.34-2.87 mCi) was 
placed in a vial and evaporated to dryness without the aid of acetonitrile. Dried 
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absolute ethanol (150 μL) was added to the vial followed by a 1 mg/mL solution (50 
μL) of the ligand (6, 10, 11, 20, 21, 23 or 24) in dried absolute ethanol. The vial was 
sealed, vortexed for 20-40 seconds and suspended in a water bath (at 75-85 °C) for 
20-60 minutes. The reaction vial was allowed to cool to room temperature, after 
which quality control was employed on the product (28-34). 
 
5.2.4.1. Analysis of [67Ga]-2-acetylpyridine thiosemicarbazone, 28. 
 
HPLC: tr = 5.5 min (87 %). 
 
5.2.4.2. Analysis of [67Ga]-2-acetylpyridine-4,4-dimethylthiosemicarbazone, 29. 
 
HPLC: tr = 15.6 min. (>99 %). 
 
5.2.4.3. Analysis of [67Ga]-2-formylpyridine-4,4-dimethylthiosemicarbazone, 30. 
 
HPLC: tr = 13.0 min. (90 %). 
 
5.2.4.4. Analysis of [67Ga]-2-formylpyridine-4-phenylthiosemicarbazone, 31. 
 
HPLC: tr = 13.0 min. (90 %). 
 
5.2.4.5. Analysis of [67Ga]-2-acetylpyridine-4-phenylthiosemicarbazone, 32. 
 
HPLC: tr = 13.8 min. (>99 %). 
 
5.2.4.6. Analysis of [67Ga]-2-formylpyridine ethane-1,2-dithiosemicarbazone, 33. 
 
HPLC: tr = 10.7-11.5 min. (95 %). 
 
5.2.4.7. Analysis of [67Ga]-2-acetylpyridine ethane-1,2-dithiosemicarbazone, 34. 
 
HPLC: tr = 11.3-12.5 min (>99 %). 
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5.2.5. Synthesis of poly(aryl)ether dendrimers ligands (and wedges). 
 
5.2.5.1. Synthesis of 2,3-bis(2-methyl-4-hydroxylphenylimino) butane, 35.24 
 
N N OHHO
 
35 
 
Reaction was performed under inert atmosphere.  A mixture of 2,3-butadione (912 
mg, 10.6 mmol), 2-methyl-4-hydroxyaniline (3.25 g, 26.4 mmol) and formic acid (0.25 
mL) was stirred in dry MeOH (35 mL) at room temperature for 24 h. The mixture was 
concentrated to less than half.  The reaction mixture was stored at -16 °C for 24 
hours to precipitate out any product. A dark precipitate was observed to have formed 
after storage, after which the precipitate was recovered by filtration. After 
recrystallisation from hot methanol, 35 (1.1g, 40%) was obtained as a yellow solid. 
Melting point = 122–125 °C (Lit. M. P. = 122-126 °C24).  1H-NMR (400 MHz, 
acetone-d6):  2.03 (6H, s, aryl-Me), 2.09 (6H, s, -N=CMe), 6.45–6.75 (6H, m, Haryl), 
7.99 (2H, br s, -OH). FT-IR (KBr pellet):  (C=Nimine) 1629 cm-1 (s). 
 
5.2.5.2. Synthesis of methyl p-bromomethylbenzoate (G0 wedge), 36.25 
 
BrH3CO
O
a
a b
b
 
36 
 
A solution of methyl p-hydroxymethylbenzoate (1.0013 g, 6.0 mmol) in dry toluene 
(30 mL) was stirred under argon at 0 °C. Phosphorus tribromide (0.19 mL, 2.0 mmol) 
was added dropwise to the solution which was then allowed to warm to room 
temperature. After 2 hours, the reaction mixture was evaporated to dryness and 
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partitioned between water (20 mL) and CH2Cl2 (20 mL).  The aqueous layer was 
extracted with CH2Cl2 (4 x 20 mL) and the combined extracts were dried and 
evaporated to dryness to give 36 (1.19 g, 87 %) as a white crystalline solid. Melting 
point = 51-53 °C (Lit. M. P. = 53-55 °C26).  1H-NMR (400 MHz, CDCl3):  3.90 ppm 
(3H, s, OCH3), 4.48 ppm (2H, s, CH2Br), 7.44 ppm (2H, d, 3J = 7.84 Hz, Hb), 7.98 
ppm (4H, d, 3J = 7.73 Hz, Ha). 
 
5.2.5.3. Synthesis of dendritic benzyl alcohol (G1), 37.25 
 
OH
O
O
H3CO
O
H3CO
O
a
a
b
c
c
c
cd
d
d
d  
37 
 
A mixture of methyl p-bromomethylbenzoate (0.500 g, 2.18 mmol), 3,5-
dihydroxybenzyl alcohol (0.152 g, 1.09 mmol), potassium carbonate (0.377 g, 1.50 
mmol) and 18-crown-6 (0.577 g, 2.18 mmol) in dry acetone (15 mL) was heated at 
reflux (60°C) and stirred vigorously under nitrogen for 24 hours. The mixture was 
allowed to cool to room temperature and was evaporated to dryness under reduced 
pressure. The residue was partitioned between water (8 mL) and CH2Cl2 (8 mL) and 
the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined extracts 
were dried (MgSO4) and evaporated and the product (37) was isolated as a white 
solid (63%).  Melting point = 56-59 °C. 1H-NMR (300 MHz, CDCl3):  3.66 ppm (1H, 
s, OH), 3.92 ppm (6H, s, OCH3), 4.62 ppm (2H, s, CH2OH), 5.10 ppm (4H, s, -OCH2-
), 6.51 ppm (1H, t, 3J = 2.18 Hz, Hb), 6.61 ppm (2H, d, 3J = 2.23 Hz, Ha), 7.47 ppm 
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(4H, d, 3J = 8.61 Hz, Hc), 8.00 ppm (4H, d, 3J = 8.48 Hz, Hd). FT-IR (KBr pellet):  
(C=O) 1715 cm-1 (m). 
 
5.2.5.4. Synthesis of dendritic benzyl bromide (G1 wedge), 38.25 
 
Br
O
O
H3CO
O
H3CO
O
a
a
b
c
c
c
cd
d
d
d  
38 
 
A mixture of dendritic benzyl alcohol (G1), 37, (0.151 g, 0.344 mmol), phosphorus 
tribromide (0.065 mL, 0.688 mmol) and triphenylphosphine (0.183 g, 0.688 mmol) in 
toluene (15 mL) was stirred vigorously for 24 hours. The reaction mixture was filtered 
by gravity and was evaporated to dryness under reduced pressure. The residue was 
partitioned between water (8 mL) and CH2Cl2 (8 mL), and the aqueous layer was 
extracted with CH2Cl2 (3 x 10 mL). The combined extracts were dried (MgSO4), 
evaporated to dryness and the product (38) was isolated as a white solid (0.092 g, 
54 %). Mass Spectrometry (EI+): m/z 499.7 (100%, [M]+). Melting point = 137-140 
°C (Lit. M. P. = 139-140 °C25)  1H-NMR (300 MHz, CDCl3):  3.92 ppm (6H, s, 
OCH3), 4.24 ppm (2H, s, CH2Br), 5.10 ppm (4H, s, -OCH2-), 6.51 ppm (1H, t, 3J = 
2.17 Hz, Hb), 6.61 ppm (2H, d, 3J = 2.24 Hz, Ha), 7.47 ppm (4H, d, 3J = 8.66 Hz, Hc), 
8.03 ppm (4H, d, 3J = 8.51 Hz, Hd). FT-IR (KBr pellet):  (C=O) 1720 cm-1 (m). 
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5.2.5.5. Synthesis of generation zero (G0) ligand, 39. 
 
N N OO
OCH3
O
H3CO
O
a
b c
a
bc
d
d d
d
e
e
e
e
 
39 
 
The reaction was performed under an inert atmosphere. A solution of methyl p-
bromomethylbenzoate (36, 0.384 g, 1.679 mmol) in dry THF (15 mL) was added, 
dropwise, to a stirring solution of 2,3-bis(2-methyl-4-hydroxylphenylimino)butane (35, 
0.2045 g, 0.8125 mmol) in dry THF (15 mL), in the presence of 18-crown-6 (0.075 g, 
0.284 mmol) and potassium carbonate (2.03 g, 14.7 mmol). The reaction mixture 
was allowed to reflux for 48 hours, after which it was cooled to room temperature. 
The mixture was evaporated to dryness and partitioned between CH2Cl2, (15 mL) 
and water (15 mL). The aqueous layer was then extracted with CH2CI2 (3 x 15 mL) 
and the combined extracts were dried (MgSO4) and evaporated to dryness. The 
product, 39, was isolated as an orange/brown solid (0.28 g, 57 %). Melting point = 
149-153 °C.  Mass Spectrometry (ESI): m/z 593.3 (100%, [M+H]+). 1H-NMR (400 
MHz, DMSO-d6):  2.03 ppm (6H, s, aryl-CH3), 2.04 ppm (6H, s, -N=C(CH3)-), 3.81 
ppm (6H, s, -OCH3), 5.63 ppm (4H, s, -CH2-), 6.58 ppm (2H, d, 3J = 2.27 Hz, Hc), 
6.80 ppm (2H, d, 3J = 2.24 Hz, Hb), 6.90 ppm (2H, s, Ha), 7.56 ppm (4H, d, 3J = 8.62 
Hz, Hd), 7.93 ppm (4H, d, 3J = 8.52 Hz, He). FT-IR (KBr pellet):  (C=Nimine) 1638 cm-1 
(m). 
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5.2.5.6. Synthesis of generation one (G1) ligand, 40. 
 
NO
O
O
O
O
OCH3
OCH3
2
a
b c
d
d
e
f
f
f
f
g
g
g
g
1
2
2
 
40 
 
The reaction was performed under an inert atmosphere. A solution of dendritic 
benzyl bromide (G1 wedge) (38, 0.090 g, 0.18 mmol) in dry THF (10 mL) was added, 
dropwise, to a stirring solution of 2,3-bis(2-methyl-4-hydroxylphenylimino)butane (35, 
0.036 g, 0.090 mmol) in dry THF (10 mL), in the presence of 18-crown-6 (0.010 g, 
0.030 mmol) and potassium carbonate (0.40 g, 15.8 mmol). The reaction mixture 
was allowed to reflux for 48 hours, after which it was cooled to room temperature. 
The mixture was evaporated to dryness and partitioned between CH2Cl2 (15 mL) and 
water (15 mL). The aqueous layer was then extracted with CH2CI2 (3 x 15 mL) and 
the combined extracts were dried (MgSO4) and evaporated to dryness. The product, 
40, was isolated as an orange oil (28 %).  The product could not be isolated as a 
solid.  1H-NMR (300 MHz, CDCl3):  2.10 ppm (12H, m, aryl-CH3 + N=C(CH3)-), 3.92 
ppm (12H, s, -OCH3), 4.98 ppm (4H, s, -CH21O-), 5.11 ppm (8H, s, -CH22O-), 6.50 
ppm (2H, t, 3J = 2.34 Hz, He), 6.58 ppm (4H, s, Hd), 6.62 ppm (2H, d, 3J = 2.23 Hz, 
Hc), 6.86 ppm (2H, d, 3J = 2.61 Hz, Hb), 6.97 ppm (2H, s, Ha), 7.56 ppm (8H, d, 3J = 
8.52 Hz, Hf), 8.05 ppm (4H, d, 3J = 8.45 Hz, Hg). FT-IR (CH3Cl, NaCl):  (C=Nimine) 
1636 cm-1 (m). 
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5.2.6. Synthesis of poly(aryl)ether dendrimer complexes. 
 
5.2.6.1. Synthesis of generation zero (G0) complex, 41. 
 
 
N N OO
OCH3
O
H3CO
O
a
b c
a
bc
d
d d
d
e
e
e
e
Pd
Cl Cl
 
41 
 
A mixture of PdCl2(COD) (0.0458 g, 0.161 mmol) and the G0 ligand 39 (0.112 g, 
0.189 mmol) was stirred in dry CH2Cl2 (15 mL) for 24 hours. The yellow-orange 
precipitate that had formed was recovered by suction filtration and washed with 
CH2Cl2 to give 41 (0.084 g, 58 %) as a yellow-orange powder. Melting point = 
decomp. > 290 °C. 1H-NMR (400 MHz, DMSO-d6):  2.06 ppm (6H, s, aryl-CH3), 
2.07 ppm (6H, s, -N=C(CH3)-), 3.84 ppm (6H, s, -OCH3), 5.19 ppm (4H, s, -CH2-), 
6.64 ppm (2H, d, 3J = 2.28 Hz, Hc), 6.87 ppm (2H, d, 3J = 2.24 Hz, Hb), 6.98 ppm (2H, 
s, Ha), 7.60 ppm (4H, d, 3J = 8.60 Hz, Hd), 7.99 ppm (4H, d, 3J = 8.52 Hz, He). FT-IR 
(KBr pellet):  (C=Nimine) 1578 cm-1 (m). 
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5.2.6.2. Synthesis of generation one (G1) complex, 42. 
 
NO
O
O
O
O
OCH3
OCH3
2
a
b c
d
d
e
f
f
f
f
g
g
g
g
1
2
2
Pd
Cl Cl
 
42 
 
A mixture of PdCl2(COD) (0.0255 g, 0.089 mmol) and the G1 ligand 40 (0.0501 g, 
0.044 mmol) was stirred in CH2Cl2 (10 mL) for 24 hours. No precipitate had formed 
thus all the solvent was removed to give an orange oil.  A minimum volume of 
CH2Cl2 (1 mL) was added and the dissolved product was added to a reservoir of 
stirring diethyl ether.  Upon addition an orange solid precipitated out of solution.  The 
solid was recovered by suction filtration and washed with diethyl ether to give 42 
(0.042 g, 73 %) as an orange solid.  1H-NMR (400 MHz, CDCl3):  2.10 ppm (12H, m, 
aryl-CH3 + N=C(CH3)-), 3.92 ppm (12H, s, -OCH3), 4.98 ppm (4H, s, -CH21O-), 5.11 
ppm (8H, s, -CH22O-), 6.50 ppm (2H, t, 3J = 2.34 Hz, He), 6.58 ppm (4H, s, Hd), 6.62 
ppm (2H, d, 3J = 2.25 Hz, Hc), 6.86 ppm (2H, d, 3J = 2.62 Hz, Hb), 6.97 ppm (2H, s, 
Ha), 7.56 ppm (8H, d, 3J = 8.52 Hz, Hf), 8.05 ppm (4H, d, 3J = 8.42 Hz, Hg). FT-IR 
(KBr pellet):  (C=Nimine) 1571 cm-1 (m). 
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5.3. Stability studies of radiolabelled gallium(III) 
thiosemicarbazones 
 
For the stability studies, the radiolabelled complex (28-34) in an ethanolic solution 
(200 µL) was evaporated to dryness using a flow of N2 gas and heat. Subsequently, 
saline solution (50 µL) or bovine serum (50 µL) was added to the vials containing the 
evaporated complex. The vials were parafilmed and vortexed (30-60 seconds). Each 
vial was placed in an oven (at 37°C) for 30, 60 and 120 minutes, respectively (i.e. the 
stability of each radiolabelled complex was tested in saline and bovine serum after 
30, 60 and 120 minutes incubation at 37°C). The vials were removed at the 
prescribed times, and acetonitrile (100 µL) was added to each vial. The vials were 
vortexed, followed by quality control being employed on each vial. 
 
5.4. Effect of water on labelling efficiency 
 
The same procedure as for the general synthesis of the radiolabelled gallium(III) 
thiosemicarbazone was followed, except water (5, 10, 20 and 40 % of the respective 
reaction mixtures) was added to the ethanolic reaction solution. 
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